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Micro and Nanoscale Aptasensors for Detection of Low Molecular Weight Biomarkers 
Towards Clinical Diagnostic Applications  
Jaeyoung Yang 
Biosensors have been developed for their potential applications to clinical 
diagnostics, particularly for detection of disease-relevant biomarkers. As affinity 
biosensors have emerged for the application, aptamers, i.e., oligonucleotide receptors, 
have gained much attention due to their ability to offer high affinity, specificity, stability, 
and rapid, low-cost production. While aptamer-based biosensors, called aptasensors, have 
shown great promise as a clinical assay tool, their sensitive detection of low molecular 
weight biomarkers is challenging. In this thesis, we present microfluidic aptasensors for 
label-free and sensitive detection of low molecular weight analytes by focusing on 
arginine vasopressin (AVP), an oligopeptide hormone and a clinically important 
biomarker. 
We first present an integrated microfluidic aptasensor for label-free detection of 
AVP by mass spectrometry. The integrated device selectively extracts AVP from human 
plasma ultrafiltrate samples and then repeatedly deposits the AVP on a MALDI plate for 
further analyte enrichment, thereby enabling highly sensitive AVP measurements.    
To further explore aptamer-based detection of AVP, we have developed an 
optomagnetic aptasensor capable of detecting a low molecular weight analyte using 
magnetic nanoparticles (MNPs). In this aptasensor, second to be presented in the thesis, 
an inhibition assay principle is used, in which degrees of MNP clustering depend on the 
ATP concentration. The clustering state is then measured by an optomagnetic readout 
 
 
system that provides information about the distribution of cluster sizes, thus enabling us 
to relate the signal to the analyte concentration in a simple mix-and-read manner. A 
proof-of-concept demonstration of the sensor operation is provided using adenosine 
triphosphate (ATP) as a model small-molecule analyte. 
We next exploit surface-enhanced Raman spectroscopy (SERS) for detection of 
AVP. A SERS-active substrate with aptamer-functionalized leaning nanopillars is used 
for sensitive and specific detection of AVP labeled with a Raman tag. Large area Raman 
mapping on the substrate enables reliable SERS-based AVP quantification, and 
microfluidic integration allows rapid and efficient analyte detection. Lastly, a competitive 
binding assay format is employed for label-free detection of AVP. 
We finally present a microfluidic aptasensor that integrates aptamer-based 
selective analyte preconcentration with conductance-based graphene nanosensing for 
detection of AVP. In the integrated device, low-abundance AVP is enriched via solid-
phase aptamer-based selective preconcentration, and then measured by a graphene field-
effect transistor (FET)-based nanosensor through aptamer-based competitive binding, 
allowing sensitive and label-free detection of AVP.  
We conclude the thesis by a discussion of directions for future work, proposing 
strategies for pursuing technological advancements to ultimately enable highly sensitive 
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Chaper 1. Introduction 
The demand for advanced biosensors is ever increasing as various disease 
biomarkers are discovered at explosive numbers; the detection of these biomarkers in 
clinical diagnostics is critically important for the national and international efforts to 
improve human healthcare. Aptamers, i.e., oligonucleotide receptors, have been used as 
molecular recognition elements in biosensors due to their high specificity, affinity, 
stability, and rapid and economical production. While aptamer-based biosensors, called 
aptasensors, have shown great promise as a clinical diagnostic tool, their sensitive 
detection of low molecular weight biomarkers is challenging. In this thesis, we develop 
aptasensors toward sensitive and label-free detection of low molecular weight biomarkers, 
with the long-term goal of ultimately enabling highly sensitive detection of such analytes 
in clinical settings for the improvement of healthcare.    
 
1.1. Biosensors 
Overview. Biosensors are analytical devices that convert biological recognition 
events into measurable signals via physicochemical transduction processes (Figure 1.1) 
[1-3]. They typically consist of two key components, a biological recognition element 
which interacts with analytes of interest (e.g., antibodies, enzymes, aptamers, nucleic 
acids, and whole cells), and a signal transducer which identifies the resultant biological 
product and generates corresponding signals that can be read qualitatively or 
quantitatively (e.g., optical [4-6], electrochemical [7-9], mechanical [10, 11], and 
magnetic [12, 13]). Since the introduction of the first biosensor in 1962, which 




biosensors have involved the detection and analysis of various analytes including ions, 
small molecules, peptides, proteins, viruses, bacteria, and cells for their applications to 
diverse fields such as clinical diagnostics, drug development, environmental monitoring, 
and food inspection.   
 
Figure 1.1. Concept of biosensors with various types of molecular recognition elements 
and signal transduction methods. 
 
Affinity Biosensors. A particularly important class of biosensors comprises 
affinity biosensors, which rely on highly specific affinity recognition elements, such as 
antibodies, protein receptors, lectins, and nucleic acids [15]. Due to their high affinity and 
commercial availability, antibodies are the most widely used molecular recognition 
element in affinity biosensors. However, antibodies also exhibit several limitations, 
including low temperature stability [16], high production cost, and large batch-to-batch 
variability. More importantly, the antibody production utilizes immunogenic responses of 
animals against a target, thus often fails for a target which is non-antigenic, toxic or too 




To improve the performance of affinity biosensors, tremendous efforts have been 
directed in parallel (1) to develop novel sensing technologies, and (2) to develop and 
synthesize a new class of affinity recognition elements.  
On one hand, progresses in micro and nanotechnologies have been offering high 
sensitivity, throughput and portability in biosensing by (1) providing novel materials with 
ultrahigh sensitivity and large surface-area-to-volume ratio, (2) exploring unique physical 
phenomena at molecular/atomic levels, and (3) enabling the integration of all necessary 
components within a miniaturized platform. Microfluidic technologies permit the 
construction of a compact device performing the entire analytical processes (e.g., capture, 
purification, separation, transport, mixing, and signal transduction), which, referred to as 
a lab-on-a-chip (LOC) system, can enable rapid and efficient sample analysis in an 
integrated manner.  
On the other hand, significant progresses in biochemistry, molecular biology and 
synthetic chemistry made it possible to create a new kind of synthetic affinity receptors, 
such as peptide nucleic acids (PNAs) [18] and nucleic acid aptamers [19, 20], possessing 
high affinity, specificity, and stability. Because the performance of biosensors is largely 
dependent on binding properties of an employed recognition element, the use of such 
synthetic receptors allowed the development of highly sensitive and specific biosensors. 
 
1.2. Biomarker Detection in Clinical Diagnostics 
Biomarkers are measurable biological indicators that can be used to assess normal 
physiological processes, pathogenic processes or pharmacological responses to 
therapeutic intervention [21, 22]. Because the state of a disease is linked to the deviation 




detection of diseases and monitoring therapeutic progresses in clinical diagnostics. 
Therefore, the accurate measurement of specific disease-related biomarker levels in 
human patient samples is exceedingly important in clinical settings. Biomarkers are 
discovered at several different levels, including small molecules, peptides, proteins, and 
nucleic acids, for various diseases. For example, cancer biomarkers such as prostate-
specific antigen (PSA), carcinoembryonic antigen (CEA), human epidermal growth 
factor receptor 2 (HER2/neu) and platelet-derived growth factor (PDGF) can be used for 
diagnosis and monitoring of prostate, colon, breast and bladder cancers, respectively, by 
measuring their serum or urinary levels [23, 24]. For another example, C-reactive protein 
(CRP) is known as a predictive biomarker as its elevated level indicates an increased risk 
of diabetes [25] or cardiovascular diseases [26]. Recent study also finds that the thrombin 
level can be used for monitoring of multiple sclerosis, a neuroinflammatory disease [27].  
With the explosive number of disease relevant biomarkers discovered over the 
past few decades, there is an increasing demand of clinical tests for detection and 
monitoring of biomarker levels in clinical diagnostics. However, conventional techniques, 
such as immunoassays and microbial culture-based assays, do not meet the current 
clinical needs as they require time-consuming procedures, labor-intensive work, and 
bulky and costly equipment under centralized laboratory settings.  
 
1.3. Aptamer-Based Biosensors for Biomarker Detection 
To satisfy the unmet clinical needs aforementioned, biosensor technologies have 
gained considerable attention as they can serve as a sensitive, rapid, low-cost and 




in clinical settings, we in this thesis employ nucleic acid aptamers as affinity recognition 
elements in proof-of-principle biosensors.       
 
1.3.1. Aptamers 
Aptamers are single-stranded DNA or RNA molecules that can specifically 
recognize their target molecules. Upon binding to a target, aptamers change their 
conformation into a molecular architecture in which the target molecule is embedded as 
an intrinsic part of the aptamer structure via a combination of multiple recognition 
mechanisms such as stacking of flat moieties, shape complementarity, hydrogen bonding, 
electrostatic interaction, and hydrophobic interaction [19, 20], thus this binding reaction 
is highly specific. Furthermore, because aptamers are selected based on the ability to bind 
to a target, they typically possess a high binding affinity, comparable to antibodies or 
other natural receptors. In addition to their high affinity and specific recognition ability, 
aptamers have several advantages over antibodies [28], including higher chemical and 
environmental stability, a wider availability of chemical modification. Furthermore, 
aptamers can be synthetically developed for virtually any target (e.g., ions, small 
molecules, peptides, proteins, and cells) (Figure 1.2) through in vitro selection processes, 
eliminating the need for laboratory animals in in vivo antibody development, thus the 
aptamer production is rapid and inexpensive with minimal batch-to-batch variability. 
Lastly, aptamer-target complexes can be generally dissociated by external stimuli such as 
temperature, pH, and ionic strength. This reversibility of aptamer binding is highly 
attractive in biosensors as it enables recovery of analytes for further analysis, and allows 





Figure 1.2. Schematic representations of molecular recognitions between nucleic acid 
aptamers (grey) and their targets (orange), when the target is (a) arginine (amino acid), (b) 
arginine-rich peptide derived from human immunodeficiency virus (HIV-1) protein, and 
(c) bacteriophage MS2 coat protein [29] 
 
1.3.2. Aptasensors for Biomarker Detection 
Due to their advantages, aptamers have been employed as a molecular recognition 
element that interfaces with various signal transducers in biosensors. Aptamer-based 
biosensors, called aptasensors, have also demonstrated their abilities to detect clinically 
relevant biomarkers for their potential applications in clinical diagnostics [30-32]. Vance 
et al. recently reported a plasmonic aptasensor for detection of C-reactive protein (CRP), 
a biomarker for cardiovascular disease, from human serum [33]. In the aptasensor, 
surface plasmon resonance imaging (SPRi) technique was used to measure target 
binding-induced refractive index changes at metal/media interfaces, when the gold 
surface was functionalized with a CRP-specific aptamer. For signal amplification, 
sandwich binding assay configuration was adopted, in which aptamer-functionalized 




surface, achieving ultrasensitive detection of CRP as low as 43 aM [10
-18
M]. Xiao et al. 
reported an electrochemical aptasensor for detection of thrombin, a biomarker for 
multiple sclerosis and thrombosis, from human serum [34]. The aptasensor is fabricated 
by attaching methylene blue (MB) to the thrombin-binding aptamer immobilized on a 
gold electrode. In the absence of thrombin, the MB label is close to the electrode surface, 
facilitating the electron transfer. Upon target binding, the aptamer folds into its binding 
structure, decreasing the electron transfer efficiency. The aptasensor demonstrated the 
thrombin detection at concentrations down to 6.4 nM.    
 
1.3.3. Aptasensors for Low Molecular Weight Biomarker Detection 
While identified biomarkers have been primarily focused on proteins and genes, 
more recent studies suggest that low molecular weight biomolecules such as peptide 
hormones or small molecule metabolites have close relevance to cancers and other 
pathological conditions [35-40], showing their potential use as biomarkers for disease 
diagnosis and therapeutic intervention in clinical settings. 
Although the number of low molecular weight biomarkers is rapidly growing, the 
development of highly sensitive aptasensors for such analytes, including oligopeptides 
and small molecules, remains to be challenging because of following limitations. First, 
simple binding-based assays which measure the occurrence of aptamer-target binding are 
frequently not effective or sensitive for detection of such analytes. Because of their small 
size as well as low in molecular weight and electrical charge, the direct binding of the 
low molecular weight analytes at sensor surfaces in general does not produce a 




plasmon resonance (SPR), cantilever, quartz crystal microbalance (QCM), field-effect 
transistor (FET), and electrochemical. Next, sandwich binding assays, a commonly used 
and powerful signal amplification method in which a secondary probe (aptamer) with a 
signal reporting (or amplifying) molecule is conjugated to another binding site of an 
aptamer-bound target molecule, are not feasible for low molecular weight analytes. This 
is due to the fact that in such small-target binding, the target molecule is normally 
inserted into a binding pocket of aptamer, leaving little part for interaction with the other 
probe [29]. Furthermore, the intrinsically low binding affinity of aptamers for low 
molecular weight targets, due to lack of availability of functional group and structural 
motif within such targets [41] and high vulnerability of signal interference from other 
larger molecules in complex biological samples [42], adds a difficulty in achieving the 
sensitive detection of low molecular weight biomarkers using aptasensors.  
 
1.3.3.1. Aptasensors Based on Aptamer Engineering 
To achieve the sensitive detection of low molecular weight analytes, aptasensors 
described most commonly take advantage of the intrinsic properties of aptamers (e.g., 
nucleic acid hybridization and aptamer sequence fragmentation) and its target binding 
characteristics (e.g., conformational change).  
Aptasensors Based on Conformational Changes. To obtain a detectable signal 
from the binding of an aptamer with a low molecular weight target, aptasensors have 
used the adaptive nature of aptamer binding, i.e., upon association with a target, aptamers 
change their conformations into a well-defined three-dimensional structure that 




signaling components is attached at specific locations of an aptamer sequence that will 
undergo a target binding-induced conformational change. In the presence of a target 
analyte, the change in aptamer structure alters the local environment of the signal reporter 
molecule, thereby producing a measurable signal [30, 31]. Using this strategy, Baker et al. 
developed an electrochemical aptasensor that can detect cocaine [43]. The aptasensor was 
fabricated by tagging methylene blue (MB) to a distal end of an aptamer immobilized on 
a gold electrode. In the absence of a target, the aptamer remains to be partially unfolded. 
In the presence of the target cocaine, the aptamer folds into a three-way junction 
incorporating a cocaine molecule, which makes the electroactive methylene blue to be 
located close to the electrode, which thus alters the electron transfer state (Figure 1.3a). 
Stojanovic et al. also utilized the target binding-induced conformational change for 
aptamer-based optical detection of cocaine [44]. A cocaine binding aptamer was prepared 
by linking a fluorophore at one end of the aptamer and a quencher at the other end. In the 
absence of a target, two stems are kept at open, thus the fluorophore is allowed to emit 
light. Upon binding to cocaine, the aptamer closes and forms a three-way junction that 
adopts the target molecule. This structural change results in locating the quencher in close 
proximity with the fluorophore, thereby switching off the fluorescence (Figure 1.3b). 
This structure-switching strategy assumes that the conformational change substantially 
alters the local environment of an attached signaling molecule. However, when the 
structure information about an aptamer of interest is not available, rationally designing a 
conformational change-based aptasensor is not straightforward because labeling at a 
proper location which will generate sufficient signal changes is difficult without the 




modification steps to obtain a desirable binding characteristic. Consequently, this strategy 
is by and large empirical, thus is not easy to generalize [43, 45]. This strategy is also not 
applicable to fully folded aptamers that undergo only small changes, thus failing to 
generate detectable signals [46]. In addition, the modification of the aptamer sequence or 
attachment of signaling molecules may cause a significant loss of its binding affinity to a 
target [47].  
 
Figure 1.3. Aptasensors that used target binding-induced conformational changes for (a) 
electrochemical detection of cocaine [43] and (b) optical detection of cocaine [44].  
 
Aptasensors Based on Structure-Switching Signaling. The ability of nucleic 
acid aptamers to hybridize with their complementary sequences has also been used for 
detection of low molecular weight analytes in aptasensors. In the absence of a target, an 
aptamer is in unfolded form, hybridized with its complementary sequence. Its binding 
with a target results in the aptamer folded into a well-defined three-dimensional structure 
through adaptive binding, causing the displacement of the aptamer from its 
complementary strand. The target binding-induced dehybridization switches aptamer-
complementary strand duplexes to aptamer-target complexes, referred to as structure-




amplification is achieved by tagging an aptamer and its complementary sequence with a 
set of signal reporters, where the target binding-induced aptamer dissociation results in 
changes in the distance between the signaling components, thereby generating an 
amplified signal [48-52]. Using this strategy, Zuo et al. demonstrated an electrochemical 
aptasensor for detection of adenosine triphosphate (ATP), a small molecule and an 
energy source in metabolic processes [53]. The surface-immobilized aptamer labeled 
with electroactive compound, ferrocene (Fc), was hybridized with its complementary 
sequence. This DNA duplex is responsive to the target ATP, which thus liberates the 
complementary strand to form the aptamer-target complex. The target-binding induced 
aptamer folding results in bringing Fc molecule to nearby the electrode, which turns on 
the electron transfer and generates measurable electrochemical signals (Figure 1.4a). 
Chen et al. reported a structure-switching based optical aptasensor for detection of 
ochratoxin A (OTA), a small molecule metabolite and a mycotoxin produced by fungi 
organisms [50]. In the absence of a target, an OTA-specific aptamer labeled with a 
fluorophore hybridizes to its complementary strand labeled with a quencher moiety, 
bringing the fluorophore and the quencher into close proximity for maximum 
fluorescence quenching effect. Upon binding to target OTA, the change in the aptamer 
conformation induces the release of the quencher-labeled complementary strand, 
producing a strong fluorescent signal related to the analyte concentration (Figure 1.4b). 
Liu et al. described a structure-switching signaling aptamer-based colorimetric biosensor 
for detection of adenosine and cocaine based on the difference in color of gold 
nanoparticles between their aggregated and dispersed forms [54]. In the absence of a 




its complementary strand. Upon the addition of a small molecule target, the aptamer 
undergoes a conformational change, which results in the dissociation of aptamer-
complementary strand complexes. This structure switching causes the disassembly of the 
aggregates, consequently a visible color changes to red is induced. This hybridization-
based structure-switching strategy is relatively easy to design and generalize regardless of 
its size and structural characteristics because all nucleic acid aptamers share two distinct 
abilities: (1) to hybridize with their complementary strand, forming aptamer-
complementary duplexes and (2) to bind to their cognate ligands, forming aptamer-target 
complexes. In addition, because this strategy detects complete separation of 
oligonucleotides rather than local conformational changes within aptamers, produced 
signals are typically pronounced and largely enhanced [55]. However, because aptamer-
target binding occurs in the state that the binding site of an aptamer is hybridized with its 
complementary strand, the aptamer’s binding affinity for a target is reduced due to 
competition, blocking [45] and allosteric inhibition effect [56], thus lowering the 
sensitivity of an aptasensor. This unfavorable effect noticeably increases with low affinity 
aptamers that are common for low molecular weight analytes such as oligopeptides and 
small molecules. Nutiu et al. [45] reported that a structural-switching strategy with a low 
affinity ATP-binding aptamer resulted in the apparent Kd value which is about 60-fold 





Figure 1.4. Aptasensors based on structure-switching signaling for (a) electrochemical 
detection of ATP [53] and (b) optical detection of OTA [50]. 
 
Aptasensors Using Split Aptamers. In this strategy, an aptamer is split into two 
strands, each of which does not solely bind to a target molecule. By the addition of a 
target, these two fragments of an aptamer assemble to form a specific structure that can 
bind to the target molecule. This split aptamer-based strategy allows the application of a 
sandwich binding assay configuration for detection of low molecular weight analytes 
with a single binding site, enabling signal amplification for sensitive analyte detection 
[30, 31, 57-59]. Zuo et al. presented an electrochemical split aptasensor  for detection of 
cocaine and ATP [60]. After an aptamer was split into two fragments, one of which was 
immobilized on a god electrode, and the other one is labeled with the redox moiety 
methylene blue (MB). Target binding-induced assembly of these two halves of the 
aptamer brings methylene blue towards the electrode surface, which results in electron 
transfer monitored by voltammetry (Figure 1.6a). Ruslinda et al. developed an optical 
split aptasensor for detection of Tat peptide, an oligopeptide which is composed of 12 
amino acids and derived from human immunodeficiency virus (HIV)-1 Tat protein [61]. 




the target peptide is captured by assembly of two halves of an aptamer on a sensor 
surface, and the optical signal is reported from a fluorophore attached to the secondary 
aptamer fragment (Figure 1.6b). Although these aptasensors showed excellent specificity 
to their targets, the general application of this strategy is limited because reliable methods 
for developing a new split aptamer are lacking [57] and this assembly-based target 
binding is typically feasible only for aptamers with a specific structure in their original 
forms, such as three-way junctions. In addition, the affinity of aptamer-target binding can 
be significantly reduced due to the fact that the binding occurs from a trimolecular 
reaction instead of a bimolecular interaction with an original aptamer form [31], lowering 
the sensitivity. 
 
Figure 1.5. Aptasensors that used split aptamers for (a) electrochemical detection of 
cocaine and ATP [60], and (b) optical detection of Tat peptide derived from HIV-1 
protein [61]. 
 
While significant advances have been made, the aforementioned strategies that 
utilize the intrinsic properties or binding characteristics of aptamers have been 
demonstrated only for a small set of low molecular weight targets (e.g., adenosine, ATP, 




the majority of other targets are still poorly understood and characterized. To enable the 
detection of a broader range of low molecular weight biomarkers, there is a need for 
aptasensing technologies that do not require such detailed information of aptamers. 
Aptasensors presented in this thesis aim to address this need. 
 
1.3.3.2. Other Related Work   
Label-free electrochemical aptasensors have demonstrated chemically-assisted 
detection of low molecular weight targets, such as ATP [62], cocaine [63] and 17β-
estradiol [64]. The addition of a target leads to the conformational change of an aptamer 
on sensing electrodes, causing the change in electrostatic interaction between 
electroactive probes and the negatively charged phosphate backbone of aptamers. 
Consequently, the change alters electron transfer efficiencies at the solution/electrode 
interface, thus generating signal-on and signal-off type responses (Figure 1.5a). However, 
this solution-based electrochemical detection method is susceptible to interference from 
impurities in complex samples, and thus is not proper for clinical diagnostic applications 





Figure 1.6. Aptamer-based electrochemical detection of (a) ATP and (b) D-VP using (a) 
a redox probe solution and (b) an electroactive compound (MB)-embedded graphene 
multilayer.  
 
Direct aptamer binding-based detection of low molecular weight analytes has also 
been demonstrated by exploiting unique physical properties of nanomaterials. He et al. 
developed an electrochemical aptasensor for direct detection of arginine vasopressin 
(AVP), a low molecular weight oligopeptide, using aptamer-functionalized carbon 
nanotubes (CNTs) patterned on gold electrodes [65]. Due to the excellent electrical 
conductivity of CNTs, a slight amount of electron transfer, caused by the surface 
adsorption of low charged AVP molecules, could significantly alter the electrical 
properties of CNTs, thus enabling the detection of AVP based on electrical measurements. 
Qin et al. reported an electrochemical aptasensor on aptamer-functionalized graphene 
multilayer [66] for detection of the D-enantiomer of vasopressin (D-VP). The highly 
conductive graphene multilayer film was assembled through alternate adsorption of 




detection. The binding of D-VP to the aptamer results in blocking electron transfer 
processes of methylene blue, leading to decreases in current peak (Figure 1.5b). Although 
promising, these nanomaterial-based approaches are still limited by low sensitivity or 
complicated fabrication processes.    
 
1.4. Objectives, Significance and Contributions of This Thesis 
Research 
1.4.1. Objectives and Significance 
The main objectives of this thesis research were to develop micro and nanoscale 
biosensors using aptamer-based affinity binding principles for label-free and sensitive 
detection of low molecular weight analytes, such as oligopeptides and small molecules, 
thus demonstrating the potential utility of the aptasensors in clinical diagnostics. The 
significance of this work is as follows.   
 Aptamer-Based Affinity Sensing of Low Molecular Weight Biomarkers: 
Label-free detection of low molecular weight analytes is achieved by employing 
aptamer-based competitive binding on micro/nanostructures, without the need for 
detailed information on aptamer structures and target binding mechanisms that are 
commonly required in existing aptasensing approaches for detection of low 
molecular weight targets (Section 1.3.3.1). Various aptamer-based strategies for 
specific signal enhancement are attempted (e.g., aptamer-based selective 
preconcentration, aptamer-based molecular positioning in hotspots, and aptamer-
based nanoparticle clustering) for detection of the analyte at clinically or 




 Highly Sensitive and Integrated Biosensors Using Micro/Nanomaterials: Our 
aptasensors utilize functional nanomaterials (e.g., leaning nanopillars forming 
SERS hotspots, self-assembling magnetic nanoparticles, and atomically thin 
graphene), which amplify signals by tuning their physical properties, for sensitive 
detection. Microfluidic integration of aptasensors combines the entire 
bioanalytical procedure within small volume, allowing efficient analyte detection 
with minimized sample loss and enhanced biochemical.  
 Biomarker Detection in Human Patient Samples: Our aptasensor demonstrates 
detection of a low molecular weight oligopeptide biomarker from plasma 
ultrafiltrate samples of human patients, as is desired for clinical applications. This 
is achieved by aptamer-based affinity purification of the patient sample followed 
by analyte detection. In addition, we use a nuclease-resistant RNA aptamer, 
termed Spiegelmer, as an affinity receptor in the system, thus enabling the analyte 
detection in human patient samples without the aptamer degradation caused by 
nuclease attack.  
 
1.4.2. Main Contributions 
In this thesis, we demonstrate four different aptasensors, all of which explore 
micro and nanobiosensing approaches combined with aptamer-based affinity binding. To 
demonstrate the ability of our aptasensors to detect low molecular weight biomarkers, 
this thesis research is primarily focused on detection of arginine vasopressin (AVP), 




related death, but it has been challenging to detect because of its low molecular weight 
and plasma levels.  
 Mass spectrometric detection of AVP from human plasma ultrafiltrate using 
an integrated microfluidic aptasensor: In the integrated microdevice, an 
aptamer immobilized on microbead surfaces selectively extracts and enriches 
AVP from human plasma ultrafiltrate. After washing beads with buffer, thermally 
activated release of AVP into purified water enables isocratic elution of the 
analyte. The purified AVP is then repeatedly deposited, via PZT spotting, on a 
spot on the MALDI plate to further enrich AVP on the spot. Coupled to mass 
spectrometry, our approach demonstrates the detection of low-abundance AVP 
from human patient plasma ultrafiltrate samples, and is thus attractive for clinical 
diagnostic applications.  
 Optomagnetic detection of ATP based on the clustering of aptamer-
functionalized magnetic nanoparticles: Our optomagnetic aptasensor uses 
magnetic nanoparticles (MNPs) which form magnetic clusters whose sizes vary 
depending on the analyte concentration. To demonstrate the detection of small 
molecule ATP, an inhibition assay configuration is employed, where two 
mutually exclusive binding reactions (aptamer-ATP binding and DNA 
hybridization between an aptamer and its partial complementary sequence) occur 
between aptamer- and linker DNA-conjugated MNPs. The presence of ATP 
hinders the MNP clustering induced by aptamer-linker hybridization, thus 
enabling us to relate degrees of MNP clustering to the ATP concentration. The 




that can measure the distribution of cluster sizes. Using the optomagnetic 
aptasensor, we achieve label-free, specific, and quantitative detection of ATP at 
physiologically relevant concentrations.  
 Surface-enhanced Raman spectroscopic detection of AVP via large area 
Raman mapping on aptamer-functionalized leaning nanopillars: A substrate 
densely packed with aptamer-functionalized leaning nanopillars is used as a 
SERS-active platform. Leaning nanopillars produce enhanced Raman signals 
which represent the presence of Raman tag-labeled AVP adsorbed on the 
nanopillar surface by aptamer-based affinity binding. By conducting large area 
Raman mapping, the statistical reliability and reproducibility in quantitative SERS 
analysis is improved, thus enabling reliable biomolecular quantification. The 
substrate is further integrated into a microfluidic system which facilitates 
temperature control and substrate functionalization. In the microfluidic device, 
aptamer-based competitive assay is also tested for label-free detection of AVP, 
thus showing the potential of the device as a quantitative diagnostic tool detecting 
low molecular weight biomarkers.  
 Graphene conductance-based detection of AVP in an integrated microfluidic 
aptasensor: Our integrated device combines aptamer-based specific 
preconcentration and conductance-based graphene nanosensing on a single 
microchip. In the device, AVP is selectively captured and enriched on microbead 
surfaces by aptamer-based affinity binding, and then transferred to the graphene 
nanosensor that exploits an aptamer-based competitive assay to transduce the 




graphene. Our approach allows label-free, sensitive, and quantitative detection of 
AVP as required in clinical settings. 
 
1.4.3. Organization of This Thesis 
This thesis is organized as follows: Chapter 2 presents an integrated microdevice 
capable of thermally controlled affinity extraction using aptamer-functionalized 
microbeads and piezoelectrically driven sample deposition for label-free mass 
spectrometric detection of AVP from human plasma ultrafiltrate samples. Chapter 3 
presents an optomagnetic aptasensor for detection of small molecule ATP based on the 
clustering of MNPs. By employing an aptamer-based inhibition assay configuration, the 
degree of MNP clustering is found to be well related to the ATP concentration, which we 
believe can be further extended to AVP detection in point-of-care settings. Chapter 4 
presents a SERS-based aptasensor for detection of AVP within a microfluidic device 
incorporating aptamer-functionalized nanopillars. While taking the ultrasensitive 
detection capability of SERS, our approach addresses the limitations of current 
quantitative SERS approaches by performing large area Raman mapping on uniformly 
distributed leaning nanopillars. This approach allows reliable and reproducible 
quantification of Raman tag-labeled AVP at picomolar concentrations, promising for 
clinical diagnostic application. Chapter 5 describes an aptamer-based graphene 
nanosensor integrated in a microfluidic device for detection of AVP. The device 
combines aptamer-based selective preconcentration and conductance-based graphene 
nanosensing, achieving the detection of AVP at clinically relevant picomolar 




assay. All the presented systems have been successfully developed and tested for 
detection of AVP in Chapters 2, 4 and 5, or adenosine triphosphate (ATP) in Chapter 3, 




Chaper 2. An Integrated Microfluidic Aptasensor Coupled to 
Mass Spectrometry    
In this chapter, we present a microfluidic aptasensor coupled to mass 
spectrometry for detection of a low-molecular weight biomarker in human patient 
samples. Using a microfluidic device that integrates aptamer-based specific analyte 
extraction, isocratic elution, and repeated depositions followed by matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, we achieve 
sensitive and label-free detection of arginine vasopressin (AVP), an oligopeptide 
biomarker, in human plasma ultrafiltrate. In the purification chamber of the aptasensor, 
an aptamer is immobilized on microbead surfaces to specifically extract AVP from the 
plasma ultrafiltrate sample via affinity binding. Next, thermally induced reversible 
disruption of the aptamer-AVP complexes is effected by an integrated microheater and 
temperature sensor, and used to release the AVP into purified water, achieving isocratic 
elution. Then, the purified AVP solution is repeatedly deposited, using a piezoelectrically 
driven nanoliter-droplet ejector, onto a MALDI plate to form a micrometer-sized spot, 
achieving analyte enrichment for mass spectrometric detection of low-abundance AVP. 
We present experimental results on detecting AVP in human plasma ultrafiltrate at 
nanomolar concentrations, which can be further reduced to picomolar levels via aptamer-
based selective preconcentration. 
 
2.1. Introduction 
Matrix-assisted laser desorption/ ionization time-of-flight (MALDI-TOF) mass 




accuracy, simple operation, and rapid analysis capability [67]. Despite these advantages, 
rapid and quantitative detection of clinical biomarkers using MALDI-TOF mass 
spectrometry has been hindered by following limitations [68]. First, in detecting an 
analyte of interest from complex biological samples, ionization of the analyte is prone to 
be impeded by other biological impurities, lowering the detection sensitivity. Thus, the 
sample clean-up process is needed prior to mass spectrometry, but it requires time-
consuming and labor-intensive work. Second, the spatial distribution of analyte 
molecules is not uniform within a dried sample spot, which causes large variation of mass 
spectra shot-to-shot or spot-to-spot. Because of aforementioned limitations, the 
reproducibility of mass spectra is poor between experiments, particularly for quantitative 
analysis of biomolecules at low abundance, hindering the practical use of MALDI-TOF 
mass spectrometry for clinical diagnosis.  
We here present an integrated microfluidic aptasensor that achieves the MALDI-
TOF mass spectrometric detection of AVP, a low molecular weight oligopeptide 
biomarker, in human plasma ultrafiltrate samples. The device integrates, on a single 
microchip, the entire process of aptamer-based specific extraction, isocratic elution of 
AVP from human plasma ultrafiltrate samples, and repeated depositions for subsequent 
analysis via MALDI-TOF mass spectrometry, allowing sensitive and label-free detection 
of AVP. This approach, achieved using bead-based solid-phase extraction, temperature-
mediated isocratic elution, and piezoelectric (PZT) spotting, eliminates the need for off-
chip manual handling of samples and reagents, thus allowing the analytical procedures to 
be performed in an integrated manner within small volumes (< 10 µl) with minimized 




be available only at limited quantities. The ability of the device to sensitively detect AVP, 
an oligopeptide hormone responsible for arterial vasoconstriction that occurs in extreme 
physical trauma such as hemorrhagic or septic shock or congestive heart failure, in a 
label-free manner is also significant. While the sensitive measurement of plasma AVP 
levels is clinically important to prevent a late-phase hemorrhagic shock [69], 
conventional AVP assays such as enzyme-linked immunosorbent assay (ELISA) and 
radioimmunoassay (RIA) require labor-intensive work and time-consuming procedures 
(exceeding 24 hrs), hindering their practical use. Experimental results show that the 
aptasensor is capable of detecting AVP from human plasma ultrafiltrate at nanomolar 
concentrations, which can be further reduced to picomolar concentrations by aptamer-
based selective preconcentration, thereby demonstrating the potential utility of the device 
in clinical diagnostics.  
 
2.2. Principle, Design, and Fabrication 
2.2.1. Principle 
Aptamer-Based Selective Preconcentration. The principle of AVP detection is 
schematically described in Figure 2.1. A sample solution containing AVP and other 
biological impurities is first introduced into the purification chamber packed with 
aptamer-functionalized microbeads while the temperature inside is maintained at 37 °C, 
the optimum temperature for aptamer-AVP binding [70].  In the purification chamber, the 
aptamer selectively captures AVP molecules on the microbead surface (Figure 2.1a). The 
chamber is then flushed with a buffer solution at 37 °C to remove unbound impurities and 




with brief water washing, the chamber temperature is raised up to 60 °C, which disrupts 
the aptamer-AVP complex for isocratic elution of released AVP with purified water 
(Figure 2.1c). 
On-Spot Analyte Enrichment. The eluted AVP solution is transferred to the 
spotting chamber through the secondary channel, and is then spotted onto a thin layer of 
matrix crystal on a MALDI plate by using a PZT nanoliter-droplet ejector (Figure 2.1d). 
After the spotted droplet is evaporated, a subsequent droplet is spotted onto the same site 
(Figure 2.1e), and these repeated depositions induce the concentration of analyte 
molecules on the spot, called on-spot analyte enrichment (Figure 2.1f). A fast evaporation 
method, by which the MALDI plate is pre-coated with a uniform and thin layer of matrix 
crystal prior to experiments, is employed to improve resolution, sensitivity and 
uniformity of mass spectral acquisition [71, 72]. 
 
Figure 2.1. Principle of AVP detection using the integrated aptasensor. Top row: 




specifically captures AVP molecules from plasma ultrafiltrate samples. (b) Unbound and 
nonspecifically adsorbed molecules are removed by washing with a buffer solution and 
water sequentially. (c) Thermally-induced disruption of aptamer-AVP binding results in 
the AVP release from the aptamer, allowing the isocratic elution of AVP with purified 
water. Bottom row: On-spot analyte enrichment. (d) By PZT spotting, the eluted AVP 
solution is deposited onto a thin layer of matrix crystal on the MALDI plate. (e) After the 
droplet is dried, the following droplet is spotted onto the same site. (f) By repeated PZT 
spotting, AVP molecules are enriched on the spot. 
 
2.2.2. Design 
The integrated microdevice consists of an aptamer-based affinity purification 
chamber (volume: 2 µl), a PZT spotting chamber (volume: 5 µl), a PZT stack actuator 
and a set of resistive microheater and temperature sensor (Cr/Au) on a glass substrate 
(Figure 2.2a, b and e). Three inlets are used to separately infuse sample, washing 
buffer/water and eluting water into the chip. A supplementary bead-packing inlet is used 
to introduce microbeads which are functionalized with an AVP-specific aptamer [73] into 
the purification chamber. The introduced microbeads (diameter: 50-80 µm) are retained 
in the chamber (height: 150 µm) by two dam-like weir structures formed by the 
connection to thin microchannels (height: 20 µm) (Figure 2.2c). A solution is transferred 





Figure 2.2. Schematics of the integrated microdevice: (a) side view, (b) top view. (c) A 
micrograph of the purification chamber packed with aptamer-functionalized microbeads. 
(d) Demonstration of the pressure-driven fluid flow change. A flow of a fluorescein 
solution to the waste outlet (left) is guided to the spotting chamber when the waste outlet 
is plugged (right). (e) A photo of the packaged device.  
 
2.2.3. Fabrication 
The integrated microdevice was fabricated by bonding a polydimethylsiloxane 




temperature sensor. To fabricate SU-8 mold, layers of SU-8 were spin-coated onto a 
cleaned silicon wafer followed by UV exposure and baking steps. PDMS pre-polymer 
(Sylgard 184, Dow Corning) was then poured onto the mold and baked for 1 hr at 75 °C 
(Figure 2.3a-d). The microstructured PDMS layer was then peeled off from the mold. In 
the meantime, chrome (Cr, thickness: 5 nm) and gold (Au, thickness: 150 nm) layers 
were consecutively deposited on a cleaned glass substrate by thermal evaporation. 
Following the photolithographic patterning of the metal layers, the substrate was 
passivated with a thin PDMS layer using spin coating (Figure 2.3e-h). The PDMS layer 






Figure 2.3. Fabrication processes of the integrated microdevice. (a-c) Fabrication of a 
SU-8 mold. (d) A microstructured PDMS layer casting on the SU-8 mold. (e-h) 
Micropatterning of metallic bilayer (Au/Cr) on a glass substrate using photolithography 
for a resistive microheater and a temperature sensor. (i) Packaging of the microdevice by 




AVP, desmopressin (dDAVP), vasotocin and lysine-modified AVP (Lys-AVP) 
were purchased from American Peptide Company Inc. (Sunnyvale, CA). An AVP-




GUG GU-HS-3’), termed a Spiegelmer, was custom synthesized and biotinylated by 
ChemGenes Corporation (Wilmington, MA) via a selection process involving 
enantiomeric RNA mirror imaging for improved nuclease-resistance. An adenosine 
triphosphate (ATP)-specific aptamer (5’-ACC TGG GGG AGT ATT GCG GAG GAA 
GGT AAA AAA A-3’) was obtained from Integrated DNA Technologies Inc. (Coralville, 
IA). A streptavidin-coated polyacrylamide microbead was acquired from Thermo Fisher 
Scientific Inc. (Rockford, IL) and functionalized with aptamers via streptavidin-biotin 
links. A binding buffer solution (pH 7.4) was prepared in deionized water with Tris-HCl 
(20 mM), NaCl (150 mM), KCl (5 mM), CaCl2 (1 mM), MgCl2 (1mM) from Sigma-
Aldrich (St. Louis, MO). Cyano-4-hydroxycinnamic acid (CHCA), a MALDI matrix, was 
purchased from Protea Biosciences, Inc. (Morgantown, WV) and solvated in a volume 
ratio of 80 % acetone, 20 % isopropyl alcohol and 0.1 % trifluoroacetic acid. A PZT 
stack actuator (5 × 5 × 10 mm; widths × height) inducing 6 µm displacement with 80 V 
applied was obtained from Steiner & Martins, Inc. (Miami, FL), and a solid state relay for 
switching on/off PZT actuation was purchased from Omega Engineering Inc. (Stamford, 
CT) respectively. 
 
2.3.2. Experimental Setup and Procedure 
A schematic of the experimental setup is illustrated in Figure 2.4. Streptavidin-
coated microbeads were incubated with a biotinylated aptamer solution in a tube for 1 hr, 
allowing the aptamer immobilization onto the bead surface. Then, the aptamer-
functionalized microbeads were introduced into the purification chamber through a 




Devices were rinsed with a binding buffer solution (flow rate: 10 µl/min) prior to each 
experiment. Sample solutions at various AVP concentrations were prepared in binding 
buffer or human plasma ultrafiltrate. A sample solution (volume: 10 µl) was infused into 
the chip using a syringe pump (KD210P, KD Scientific Inc.) and incubated with aptamer-
functionalized microbeads in the purification chamber for 3 min at 37 °C. In the 
experiment for aptamer-based preconcentration (Section 2.4.3), 1 ml of sample solution 
was infused into the chip over a period of approximately 65 min (flow rate: 15 µl/min) 
while the chamber temperature was kept at 37 °C. The temperature inside the chamber 
was controlled using the integrated microheater and temperature sensor connected to 
closed-loop control with LabVIEW. After the chamber was thoroughly rinsed by flushing 
with a buffer solution (volume: 50 µl; flow rate: 10 µl/min) and purified water (volume: 
10 µl; flow rate: 10 µl/min) sequentially, a plug of purified water (volume: 10 µl; flow 
rate: 2 µl/min) was slowly flowed through the chamber at 60 °C while the other two 
inlets and the waste outlet were plugged. The eluted AVP solution was then transferred 
and filled the spotting chamber followed by 50 times deposition onto the matrix-coated 
MALDI plate. 
For the PZT actuation at a predetermined frequency, the square wave-like 
function was generated by switching on and off power supply (N5768A, Agilent 
Technologies) with a solid state relay (SSRDC100VDC, Omega Engineering) controlled 
by a function generator. In the meantime, the MALDI plate was pre-coated with a thin 





Figure 2.4. A schematic of the experimental setup. The integrated microdevice is 
operated by closed-loop temperature control and PZT actuation separately.   
 
PZT spotting was characterized by measuring droplet volumes with respect to 
pulse width, w (pulse width: 0.2-2 ms; voltage magnitude: 80 V) and applied voltage, Von 
(voltage magnitudes: 50-80 V; pulse width: 2 ms), respectively. After the spotting 
chamber was filled with water, the PZT stack actuator on top of the chamber was 
intermittently triggered by switching on/off electric voltage application. The external 
actuation generated instantaneous linear displacement of the PZT stack, thus deforming 
the top PDMS layer of the spotting chamber (2 mm thick). The spontaneous pressure 
increase in the chamber resulted in firing a droplet with a volume of 4 to 7.5 nl through a 
nozzle (a square shape of 150 µm×150 µm). It was noted that the volume dispensed 




which are related to the duration of driving stroke and physical displacement of the 
actuator respectively. In all experiments in this thesis, measurements were performed in 
triplicates (unless noted), from which averages and standard deviations were computed. 
 
Figure 2.5. Principle of PZT spotting: (a) A PZT stack actuator is placed on top of the 
spotting chamber, and plastic holders hold the actuator with the chip. (b) A PZT actuation 
is intermittently triggered by applying DC voltages (50-80 V) inducing a linear 
displacement (Δt ~ 6 µm at 80 V) of the PZT stack actuator, thus resulting in the 
deformation of the top PDMS layer (2 mm thick). Due to the spontaneous pressure 
increase in the chamber, a droplet is ejected through a square-shaped nozzle (150 
µm×150 µm). Characterization of the PZT nanoliter-droplet ejector showing the 






2.4. Results and Discussion  
2.4.1. Effects of PZT Spotting on Mass Spectrometric AVP Detection  
We first investigated effects of PZT spotting on MALDI-TOF mass spectrometry 
for AVP detection. A 100 nM AVP solution prepared in purified water was deposited once 
on the MALDI plate using pipetting (1 µl) or PZT spotting (volume: ~7 nl), which 
remained dried MALDI spots with diameters of 1.5 mm and 300 µm, respectively (Figure 
2.6a and b). Manually controlled UV laser shots (laser irradiation size ~ 150 µm) were 
irradiated onto five different locations on each spot for mass spectral acquisitions, and 
AVP peak intensities from five measurements were averaged for comparison. 
Experimental results showed that the pipetted spot produced 3 times larger spatial 
variation of AVP peak intensities (27 %), compared to a PZT spotting generated spot (9.2 
%) (Figure 2.6c), concluding that nanoliter-volume spotting can reduce the spatial 
variation of signals, which in turn improves the reproducibility of mass spectra. This 
beneficial effect arises from the fact that the MALDI spot size becomes comparable to a 






Figure 2.6. Photos of dried MALDI spots deposited by (a) pipetting (diameter: 1.5 mm) 
or (b) PZT spotting (diameter: 300 µm). Approximately 25 times smaller spot (area) was 
produced when using the PZT nanoliter-droplet ejector. Scale bars indicate 500 µm. (c) 
Averages of peak intensities from 5 measurements at different locations within a spot 
were compared between two sample deposition manners, coefficient of variations (C.V.= 
standard deviation/ mean value) were indicated  above the error bars.  
 
To determine the optimal number of deposition for AVP detection, we obtained 
mass spectra from varying the number of 100 nM AVP sample deposition. Intensities of 
the AVP peak were found to increase with the number of deposition (Figure 2.7), 




repeated depositions more than 50 times frequently dissolved a matrix layer, precluding 
MALDI measurements, thus 50 times depositions were performed for on-spot analyte 
enrichment in following experiments  
 
Figure 2.7. Determination of the optimum number of deposition for MALDI-TOF mass 
spectrometric detection of AVP at 100 nM. Intensities of the AVP peak were plotted with 
respect to the number of sample deposition. 
 
To study the effect of the multiple depositions on a spot, an AVP solution (1-100 
nM) prepared in purified water was deposited by single or 50 times spotting using the 
PZT nanoliter-droplet ejector. Intensities of the AVP peak were significantly amplified at 
all concentrations (Figure 2.8), indicating that repeated depositions result in the 
accumulation of AVP molecules on the spot. It is noteworthy that at low concentrations 
(1/10 nM) only peaks comparable to background noises (signal-to-noise ratio: S/N < 5) 
were detected by single deposition, while an appreciable AVP peak appeared by repeated 




multiple depositions can significantly lower the detection limit in MALDI-TOF mass 
spectrometric detection of AVP. 
 
Figure 2.8. The effect of multiple depositions using the PZT nanoliter-droplet ejector in 
the integrated device: mass spectra at various AVP concentrations (1/10/100 nM from the 
top) when (a) an AVP solution in purified water is deposited once, or (b) 50 times on the 
same spot.   
 
2.4.2. ATP Detection 
We investigated the specificity of the aptasensor. The device, functionalized with 
the AVP-specific aptamer, was first tested for detection of AVP at 100 nM in binding 




(Figure 2.9). On the other hand, vasotocin, an oligopeptide that differs from AVP by a 
single amino acid, yielded a mass spectral peak (at 1050 m/z) that was small compared 
with that of AVP (Figure 2.9) and could be attributed to the nonspecific physical 
adsorption of vasotocin molecules to microbead and microfluidic surfaces. Thus, while 
aptamer-based preconcentration and on-spot enrichment resulted in a significant amount 
of AVP molecules for mass spectrometric detection, the binding between the aptamer and 
the control molecule vasotocin was insignificant. In addition, when the device was 
functionalized with a control aptamer (an aptamer that binds to ATP), testing of AVP 
detection did not yield a distinctive mass spectral peak (data not shown). These results 
demonstrated that the aptasensor was specific to AVP. 
 
Figure 2.9. Specificity of the aptasensor: the device, functionalized with the AVP-
specific aptamer, was tested respectively on AVP and vasotocin (control), both at 100 nM. 
 
To reduce the experimental variability which can arises from chip processing 




amount of an internal standard was added into AVP samples. Desmopressin (dDAVP), a 
synthetic replacement for AVP with a molecular weight of 1069 Da, was chosen as an 
internal standard through the investigation of similarity in MALDI responses among 
various polypeptides (Figure 2.10).  
 
Figure 2.10. Internal standard selection: To find the best internal standard of AVP 
showing the most similar MALDI response with AVP, various polypeptides, AVP (dark 
blue diamond), dDAVP (green triangle), Lys-AVP (red square), and Vasotocin (blue 
cross), were tested in the nanomolar range. 
 
We tested the aptasensor for AVP detection in binding buffer. An AVP sample at 
varying concentrations (0.01-10 nM) with 1 nM dDAVP was prepared in binding buffer, 
and then processed through the integrated device followed by MALDI-TOF mass 
spectrometry. Resulting mass spectra displayed two peaks at 1069 m/z and 1084.5 m/z, 
which respectively represent dDAVP and AVP, while no AVP peak appeared at 10 pM 




AVP is insufficiently low for its detection below 100 pM as the dissociation constant (Kd) 
reported elsewhere is 1.7 nM at 37 °C [73]. Peak intensity ratios of AVP to dDAVP were 
calculated for relative quantification, and the ratio was found to proportionally increase 
with the AVP concentration in the range between 100 pM and 10 nM (Figure 2.11b). This 
implies that higher AVP concentrations resulted in more AVP captured by aptamer on the 
microbead surface in the aptasensor, thus inducing the larger amount of AVP on a 
MALDI spot. 
 
Figure 2.11. AVP detection in buffer: (a) Mass spectra obtained from experiments with 
AVP samples at various concentrations (0.01-10 nM) containing dDAVP at a fixed 
concentration (1 nM). (b) MALDI peak ratios (AVP/dDAVP) vs. AVP concentrations, 
showing the concentration-dependent responses in the range of 100 pM to 10 nM.  
 




also tested the AVP detection from human plasma ultrafiltrate. AVP at various 
concentrations (1-100nM) and dDAVP at a fixed concentration (10 nM) were spiked into 
a human plasma ultrafiltrate solution, which was then processed by the integrated 
aptasensor for MALDI-TOF mass spectrometric detection. Resulting mass spectra 
showed that absolute intensities of the AVP peak and the AVP concentration did not 
correlate (Figure 2.12a), indicating that biological impurities interfered with both the 
aptamer-AVP binding and the ionization of AVP molecules during the MALDI process, 
consequently increasing the experimental variability. However, the effects of such 
variations could be effectively suppressed by relative quantification with dDAVP, in 
which case the mass spectral peak ratio (AVP/dDAVP) monotonically increased with the 
AVP concentration in the nanomolar range (Figure 2.12b). These results suggest that the 
integrated aptasensor specifically extracted AVP from human plasma ultrafiltrate via 
aptamer-based affinity binding, and further enriched the extracted analyte on a MALDI 





Figure 2.12. AVP detection in human plasma ultrafiltrate (UF): (a) Mass spectra 
obtained from experiments with plasma ultrafiltrate samples spiked with AVP at various 
concentrations (1-100 nM) and dDAVP at a fixed concentration (10 nM). (b) MALDI 
peak ratio (AVP/dDAVP) vs. AVP concentration. 
 
2.4.3. Preliminary AVP detection at clinically relevant picomolar concentrations  
Related to late-phase hemorrhagic shock, plasma AVP levels vary from 1 to 500 
pM. To demonstrate AVP detection in this clinically relevant range, we combined 
aptamer-based preconcentration of AVP with on-spot analyte enrichment, for which a 
dilute AVP solution was continuously infused into the device followed by washing, 
elution, and repeated depositions on a MALDI plate. We first tested this approach for 
AVP detection in binding buffer, in which AVP concentrations were varied from 1 to 100 
pM while the dDAVP concentration was kept at 10 pM. Results showed that the peak 
ratio of AVP to dDAVP increased with the AVP concentration, confirming the ability of 




indicates that the continuous sample infusion caused aptamer-based selective 
preconcentration of AVP on microbead surfaces followed by further on-spot analyte 
enrichment, thereby enabling detection of AVP at such low picomolar concentrations. 
 
Figure 2.13. Picomolar AVP detection via aptamer-based preconcentration coupled to 
on-spot analyte enrichment. (a) In buffer: MALDI peak ratio (AVP/dDAVP) vs. AVP 
concentration in the range between 1 and 100 pM with 10 pM dDAVP. (b) In human 
plasma ultrafiltrate: Mass spectra obtained from a plasma ultrafiltrate sample spiked with 
10 pM (top) or 100 pM (bottom) AVP.     
 
Using this approach, we also conducted preliminary tests for AVP detection in 
human plasma ultrafiltrate at the clinically relevant picomolar concentrations of 10 and 
100 pM. In the resulting mass   spectra, a distinct AVP peak was observed at each of the 
concentrations in the presence of significant background peaks (Figure 2.13b). On the 
other hand, mass spectral peaks of AVP were not distinguishable from background peaks 




repeated selective extraction of AVP effectively increased the sensitivity of the 
aptasensor even in the presence of biological impurities in the human plasma ultrafiltrate 
sample. Impurities and ions that nonspecifically adsorbed to beads likely contributed 
significantly to the background peaks, whose reduction would enable the device to 
measure AVP at further lower concentrations in a more reproducible manner. For 
example, modification of bead surfaces with an anti-adsorption coating (e.g., 
polyethylene glycol [75]), while not implemented in the present proof-of-concept work, 
should significantly reduce background peaks in the mass spectra. In addition, this issue 
could be further mitigated by optimization of the device design (e.g., chamber volume 
and shape), washing methods (e.g., choice of buffer as well as washing time and flow rate) 
during the device operation, and microbead manipulation schemes (e.g., the use of 
dynamically moving magnetic beads [76]). 
 
2.5. Conclusion 
We have developed an integrated microfluidic aptasensor for label-free mass 
spectrometric detection of a low molecular weight analyte in human plasma ultrafiltrate. 
The device integrates aptamer-based specific extraction and isocratic elution of the 
analyte from human plasma ultrafiltrate samples, and PZT spotting for following 
MALDI-TOF mass spectrometric detection. AVP, a clinically important oligopeptide 
biomarker, was effectively extracted from human plasma ultrafiltrate via solid-phase 
aptamer-based affinity binding, thus allowing detection of AVP by MALDI-TOF mass 
spectrometry. The PZT spotting technique formed a dried MALDI spot as small as laser 




purified AVP solution was then repeatedly deposited on a spot, thus inducing on-spot 
analyte enrichment for improved sensitivity.  
Using the integrated device, we demonstrated label-free mass spectrometric 
detection of AVP in binding buffer and human plasma ultrafiltrate in the range of 0.1-10 
nM and 1-100 nM, respectively. Combining aptamer-based selective preconcentration of 
AVP on microbeads with on-spot analyte enrichment by repeated depositions on a 
MALDI plate, we showed that the aptasensor can further detect AVP in the clinically 
relevant concentration range of 1-100 pM. Through preliminary tests, we also 
demonstrated detection of AVP from human plasma ultrafiltrate at concentrations down 
to picomolar concentrations, showing the potential utility of our aptasensor in clinical 
settings. The sensitivity of the aptasensor can be further enhanced in future work by 
optimization of the device design and operation, such as using anti-adsorption 
modification of microbead surfaces as well as improved choice of device dimensions, 




Chaper 3. An Optomagnetic Aptasensor via Magnetic 
Nanoparticle Clustering 
In this chapter, we present an optomagnetic aptasensor that uses magnetic 
nanoparticle (MNP) clustering for detection of low molecular weight analytes. In addition 
to its ability to detect a low molecular weight analyte in a simple and label-free manner, 
the aptasensor is realized on a low-cost and compact optomagnetic readout system and is 
well suited to point-of-care diagnostics. In the aptasensor, MNPs are used as sensing 
materials onto which an aptamer and its partial complementary sequence (DNA linker) 
are separately immobilized. Using the oligonucleotide-MNP conjugates, we employ an 
inhibition assay configuration with two mutually exclusive binding reactions, aptamer-
analyte binding and aptamer-linker hybridization. Consequently, the addition of a low 
molecular weight target hinders the MNP clustering induced by the aptamer-linker 
hybridization, thereby enabling us to relate the degree of MNP clustering to the target 
concentration. The clustering state is then measured using a low-cost and compact 
optomagnetic readout system implemented with a commercial Blu-ray optical pickup unit 
(OPU). The optical signals with respect to frequencies of the magnetic field excitation 
provide information on the distribution of hydrodynamic sizes of MNPs and the clusters. 
Using this optomagnetic aptasensor, we demonstrate the detection of adenosine 
triphosphate (ATP), a small molecule analyte, in the micromolar concentration range.  
  
3.1. Introduction 
MNP-based biosensors have been developed for various biomolecules such as 




[87-90]. Owing to the low magnetic susceptibility of biological compounds, the 
manipulation and detection of MNPs in biological media are hardly interfered from 
background signals, enabling efficient and sensitive detection of biomolecules without 
additional sample purification steps. 
MNP-based detection of biomolecules has been applied to both surface-based [91-
96] and volume-based assays [77, 78, 81-85, 87, 97]. The latter typically employs 
sandwich binding-induced clustering where a molecule of interest is bound to multiple 
receptors tethered onto MNP surfaces, resulting in the agglutination of MNPs. 
Accordingly, the addition of target molecules triggers clustering of MNPs, leading to 
changes in the size and the number of agglomerated particles [12, 77, 78, 81-84, 98-101]. 
Although the volume-based MNP clustering assay is particularly appealing because it 
allows simple mix-and-read measurements with a reduced reaction time by use of 
external magnetic fields, its application for low molecular weight biomarker detection has 
been limited by requiring a target to possess multiple binding sites, which is often not 
feasible for low molecular weight analytes. Next, current technologies to detect MNP 
clusters typically measure properties such as transverse relaxation time [12, 83, 85, 101-
104], total sample magnetization [105] or light scattering [97, 105], which do not resolve 
signals with respect to particle sizes. Thus, the quantitative measurement of MNP clusters 
in a mixture is readily interfered from background signals from a large amount of single 
MNPs or variously-sized clusters, thus lowering the detection sensitivity. In addition, 
existing readout techniques require bulky and sophisticated electronic equipment such as 




temperature control, or dynamic light scattering equipment, which in turn limit their 
applicability in an out-of-the lab setting.  
We here present an optomagnetic aptasensor for detection of a low molecular 
weight analyte via size-selective measurements of MNP clusters on a low-cost and 
miniaturized platform. We employ an inhibition assay configuration, where two mutually 
exclusive binding reactions, i.e., aptamer-analyte binding and aptamer-complementary 
sequence hybridization, occur. For the inhibitive clustering assay, two types of MNPs are 
prepared, one tagged with an aptamer (apt-MNPs) and the other with a sequence partially 
complementary to the aptamer, called a DNA linker, (linker-MNPs). A hybridization 
reaction between linker-MNPs and apt-MNPs results in the formation of MNP clusters. 
Consequently, the addition of a target hinders the MNP clustering induced by aptamer-
linker hybridization, enabling us to relate the degree of MNP clustering to the target 
analyte concentration. To determine the degree of MNP clustering, i.e., the cluster sizes 
and respective amounts, we implemented an optomagnetic readout system. The system 
collects transmitted light, which is modulated by rotating MNPs under the actuation of 
external magnetic fields. The optical signal is found to be closely related to the rotational 
dynamics of MNPs, which is linked to their hydrodynamic sizes. As a result, this 
optomagnetic measurement enables us to distinguish optical signals in terms of cluster 
sizes, allowing an accurate and quantitative determination of the clustering state. 
Furthermore, to simplify and miniaturize the readout platform, we utilize a Blu-ray OPU 
which incorporates a laser diode and a photo detector, now available for less than 10 




simple sample loading, we establish a robust and miniaturized optomagnetic readout 
system at low cost.  
In this Chapter, adenosine triphosphate (ATP) is chosen as a model analyte, which 
is a small molecule (M.W.=507 Da) and an intracellular energy transporter that regulates 
cell metabolism and signaling pathways. ATP can be used as an indicator of cell viability 
[106], and thus the detection of ATP levels in the range between 0.1 and 3 mM [107] is 
essential for clinical and biological studies. Experimental results show that the change of 
the optical response obtained from the aptasensor is well correlated with the ATP 
concentration in the range of 10 µM to 10 mM, demonstrating that the aptasensor can be 
applied for detection of a low molecular weight biomarker, which can potentially be 
developed as a low-cost point-of-care diagnostic device. 
    
3.2. Principle and Design 
Aptamer-Based Inhibitive MNP Clustering Assay. The principle of ATP 
detection using MNPs is illustrated in Figure 3.1. A part of the linker sequence (CAA 
TAC TCC CCC AGG T) is designed to hybridize with the ATP-recognition site (ACC 
TGG GGG AGT ATT G) of the aptamer. Without ATP, apt-MNPs and linker-MNPs 
aggregate through successive DNA hybridization processes between aptamers and linkers 
on respective MNP surfaces (Figure 3.1a). However, in the presence of ATP, aptamers 
result folded into a three-dimensional G-quadruplex structure [108] stabilized by the 
target [29, 109, 110], which is less likely to hybridize with the linker. From a 
thermodynamic viewpoint, such stabilization means that in the presence of its cognate 




complementary sequence becomes less negative [109]. Thus, the target molecule behaves 
like an inhibitor, and the resulting affinity constant Keq' of the aptamer for its 
complementary strand is reduced by an amount depending on the target concentration [T] 
and the affinity constant of aptamer-target binding Ka, and it can be expressed as 
Keq'=Keq/(1+[T]×Ka). Consequently, as the target concentration increases, the likelihood 
of forming linker-aptamer hybrids decreases, and thus the degree of clustering between 
apt-MNPs and linker-MNPs also decreases.  
 
Figure 3.1. Principle of aptamer-based inhibitive clustering assay for ATP detection 
using MNPs. (a) When two types of MNPs (apt-MNPs and linker-MNPs) are mixed 
without ATP, hybridization between ATP-specific aptamers and linker DNA molecules 
induce agglutination of MNPs, resulting in the clustering of MNPs. (b) When apt-MNPs 
are first incubated with ATP followed by addition of linker-MNPs, aptamer binding to 
ATP reduces the likelihood of cluster formation based on an inhibition mechanism. 
 
Size-Selective Optomagnetic Measurement of Clusters. To quantitatively 
determine the clustering state of MNPs, in the optomagnetic readout system, a sinusoidal 




solution while laser light (405-nm wavelength) passes through the sample solution along 
the axis of the applied magnetic field, and is reflected back to the Blu-ray OPU by an 
adjustable mirror. The MNPs have a small remnant magnetic moment. In the absence of 
an external magnetic field, the thermal energy is sufficient to prevent formation of 
particle clusters due to magnetic interactions. However, in an applied magnetic field, 
MNPs (or clusters, if present) align preferentially with the magnetic field, and tend to 
form chain-like structures in the field direction. Upon a change of the sign of the 
magnetic field, the particles have to physically rotate to reform chain-like structures. The 
time scale for these alternate processes is given by the Brownian relaxation dynamics of 
the particles or the particle assemblies. The dynamic behavior, which forms and disrupts 
the chain-like MNP suprastructures during a cycle of the magnetic field, results in the 
modulation of the transmitted light intensity at twice the excitation frequency. The 
transmitted light modulation vs. frequency of the applied field reflects the dynamic 
behavior of MNPs in suspension. In a previous work, it was demonstrated that the 2
nd
 
harmonic component of analyzed optical signals is closely related to the Brownian 
relaxation dynamics of MNPs, which in turn gives information about the size of the 
particles in suspension [111]. 
 
3.3. Experimental 
3.3.1. Materials  
Streptavidin-coated cross-linked iron oxide (CLIO) nanoparticles with 
hydroxyethyl starch and nominal sizes of 80, 250 and 500 nm were acquired from 




ATP-specific aptamer (5’-ACC TGG GGG AGT ATT GCG GAG GAA GGT AAA 
AAA A-3’), DNA linker (5’-CAA TAC TCC CCC AGG TAA AAA AA-3’) and control 
oligonucleotide (5’-ACC TGG GGG AGT ATT AAA AAA AAA AAA AAA AAA A-3’) 
were obtained from Integrated DNA Technologies, Inc. (Coralville, IA). Other chemical 
reagents including ATP, CTP, GTP, UTP, PBS buffer, MgCl2 were purchased from 
Sigma-Aldrich (St. Louis, MO). 
 
3.3.2. Experimental Setup and Procedure 
 
Figure 3.2. A schematic (a) and a photo (b) of the optomagnetic readout setup 
 
Magnetic Nanoparticle Surface Functionalization. MNPs were repeatedly 
washed with PBS buffer four times using centrifugation followed by magnetic separation 
and resuspended at a concentration of 1 mg/ml. The MNP-suspended solution was then 
mixed with the aptamer or the linker solution, and incubated for 30 min under shaking at 
room temperature. After the incubation, the oligonucleotide-functionalized MNP 
solutions were washed with PBS with 5 mM MgCl2 (PBSM, pH 7.4) three times, and 




Experimental Protocol. Standard ATP samples at various concentrations were 
prepared in PBSM buffer solution (pH 7.4). An apt-MNP solution (1 mg/ml, 6 µl) was 
first mixed with a 6 µl of ATP sample (or with a PBSM buffer for blank experiments), 
and incubated for 1 h at room temperature. A linker-MNP solution (1 mg/ml, 6 µl) was 
then added into the sample followed by placing the sample tube in the magnetic rack for 
5 min, accumulating MNPs together. 15 min after removing the tube from the rack, 42 µl 
of PBSM buffer was added to make the final volume as 60 µl, which fills up the 
measuring chamber of the optical cuvette. 
Optomagnetic Readout. The optomagnetic readout system was developed by co-
workers at Technical University of Denmark (DTU). The lens on the Blu-Ray OPU was 
removed, and a customized circuitry was used to control the OPU laser and to extract the 
total signal arising from the OPU photodetector. Once the MNP sample solution was 
ready to measure with a volume of 60 µl, the cuvette was mounted on the sample loading 
stage located between the adjustable mirror and the Blu-ray OPU (Figure 3.2). During the 
optical signal acquisition, alternating magnetic actuation at sweeping frequencies (26 
different frequencies, from 1928 to 0.33 Hz) was applied through the MNP-suspended 
solution in the direction parallel to the light beam. The light passed through the solution 
was reflected on the mirror and returned to the photodetector of the OPU. The collected 
optical signals were analyzed using lock-in technique. 
 
3.4. Results and Discussion 




We first confirmed aptamer-based inhibitive clustering of MNPs for ATP 
detection by taking images of the clustering state of MNPs. Figure 3.3 shows images of 
(a) a single type of MNPs, (b) apt-MNPs mixed with an equal amount of linker-MNPs, 
and (c) apt-MNPs incubated with 10 mM ATP followed by addition of an equal amount 
of linker-MNPs. The top images in the figure were obtained by fluorescence microscopy 
in suspension and the bottom images were obtained by scanning electron microscope 
(SEM) after drying of a droplet. Both imaging techniques showed consistent results as 
follows. For a single type of MNPs, the MNPs were uniformly dispersed with some small 
clusters (<1 m) formed by non-specific interaction between MNPs (Figure 3.3a). For the 
mixture of apt-MNPs and linker-MNPs, large (>10 m) clusters were observed (Figure 
3.3b). When the apt-MNPs were incubated with a high concentration of ATP (10 mM) 
prior to addition of the linker-MNPs, only intermediate-sized (<5 m) clusters were 
observed (Figure 3.3c). Results showed that MNP clustering was significantly suppressed 
in the presence of a high ATP concentration, confirming that ATP acted as an inhibitor 






Figure 3.3. Inhibitive MNP clustering-based ATP detection. The top row shows 
fluorescence images acquired on MNP-suspended sample solutions and the bottom row 
shows SEM images acquired on dried spots of MNP samples. Both images were obtained 
from (a) a single type of MNPs, (b) a 1:1 mixture of apt-MNPs and linker-MNPs, and (c) 
apt-MNPs incubated with 10 mM APT followed by addition of linker-MNPs. The white 
and black scale bars indicate 20 µm and 5 µm, respectively. 
 
3.4.2. Characterization of Optomagnetic Readout  
We characterized the optomagnetic readout system using MNPs with various 
sizes. Spectra of the complex 2
nd




′)  and out-of-phase component (𝑉2
′′)  were recorded at 26 
logarithmically equidistant frequencies from f = 1928 Hz to 0.33 Hz. Figure 3.4 shows 𝑉2
′ 
vs. f for three different particle sizes with nominal diameters of 80, 250 and 500 nm. For 




and 1.9 Hz, respectively. These peak frequencies are related to the Brownian relaxation 
frequency, i.e., the frequency with the maximum out-of-phase response with respect to 
the external magnetic field. Consequently, the peak frequency varies depending on the 
hydrodynamic size of particles as larger particles tend to rotate out-of-phase at 
comparatively lower frequency with respect to smaller nanoparticles. Interestingly, the 
peak for 250 nm MNPs has an opposite sign compared to the other particle sizes, 
indicating that the chain formation/disruption dynamics of the particles modulate the 405 
nm light with an opposite sign compared to the particles with nominal sizes of 80 nm and 
500 nm. As observed in previous work [111], this phenomenon is related to the size 
dependence of the optical scattering of the individual MNPs in the Mie regime. 
 
Figure 3.4. Characterization of size-selective optomagnetic readout. Frequency spectra 
obtained from MNPs with diameters of 500, 250 or 80 nm, respectively. 
 
Next, we demonstrated the use of the method to quantify relative amounts of 




sizes (80 and 250 nm) were mixed at various concentration ratios with a fixed amount of 
80 nm MNPs and a variable amount of 250 nm MNPs. In the frequency spectra, two 
peaks at about 10 and 170 Hz were observed, representing 250 and 80 nm MNPs, 
respectively (Figure 3.5a). The relative magnitude of the peak at 10 Hz was found to 
increase in proportion with the relative amount of 250 nm MNPs (Figure 3.5b). Therefore, 
analysis of the peak magnitudes in frequency spectra enables us to quantify relative 
amounts of MNPs with various sizes. 
 
Figure 3.5. (a) Frequency spectra obtained from a mixture of 30 l 80 nm MNPs and the 
indicated volumes of 250 MNPs. Both suspensions were prepared with an MNP 
concentration of 1 mg/ml. (b) 𝑉2
′(10 Hz)/𝑉2
′(171.7 Hz) vs. concentration ratio of 250 nm 
MNPs to 80 nm MNPs. 
 
3.4.3. Optomagnetic Detection of ATP via Aptamer-Based Inhibitive MNP 
Clustering  
We then utilized the optomagnetic system to test the aptamer-based inhibition 




from the mixture of two types of 80 nm MNPs without ATP (Figure 3.6a, black squares). 
The spectrum exhibited three distinct peaks indicating that variously-sized clusters were 
present in the suspension. Based on the results shown in Figure 3.4, we hypothesize that 
the three peaks at 0.47, 2.67 and 170 Hz represent large clusters, intermediate-sized 
clusters and individual MNPs, respectively. Upon pre-incubation of apt-MNPs with 10 
mM ATP followed by the addition of linker-MNPs (Figure 3.6a, red circles), the peak 
occurring at 0.47 Hz nearly disappeared, showing that the formation of large clusters was 
dramatically suppressed by high aptamer occupancy with ATP molecules. However, 
when apt-MNPs solely existed in a sample, no appreciable difference was observed 
between the spectra with or without addition of ATP (Figure 3.6b). Both spectra showed 
the peak due to single MNPs with a shoulder appearing at around 10 Hz. This shoulder 
was attributed to small clusters generated from non-specific interactions between MNPs. 
These results are well consistent with the images presented in Figure 3.3, which also 






Figure 3.6. Inhibition-based ATP detection via optomagnetic readout. (a) Frequency 
spectra obtained from a mixture of apt-MNPs and linker-MNPs without (black square) 
and with (red circle) the pre-incubation with 10 mM ATP. (b) Frequency spectra obtained 
from apt-MNPs without (black square) and with (red circle) the pre-incubation of 10 mM 
ATP. 
 
3.4.4. Optomagnetic Detection of ATP 
Control Experiments. To study the specificity of the aptamer-ATP binding 
system, aptamer- and analyte-control experiments were conducted. First, a DNA strand, 
as a control aptamer, was designed to hybridize with the linker, but not to specifically 
recognize ATP. MNPs functionalized with the control aptamer (ctrl-MNPs) were 
premixed with ATP samples followed by addition of linker-MNPs. The addition of ATP 
did not incur any appreciable signal change from the blank sample, indicating that ATP 




MPNs (Figure 3.7a, black squares) did not form the large clusters upon mixing with 
linker-MPNs observed for the apt-MNPs (Figure 3.6a, black squares). This can be 
attributed to that the affinity constant (Keq) for the hybridization is reduced by decreased 
number of base pairing between the control aptamer and the DNA linker (16 base pairs 
with the ATP-specific aptamer, 15 base pairs with the control aptamer).  
Next, analyte-control experiments were performed with analogues of ATP (CTP, 
GTP and UTP). When the control analytes at 500 µM were allowed to interact with apt-
MNPs followed by the addition of linker-MNPs, the frequency spectra were virtually 
identical to that of the blank sample (Figure 3.7b) indicating that the control analytes 
were not recognized by the ATP-specific aptamers. The control experimental results 
demonstrate that the inhibition effect resulted from the adaptive binding of aptamers in 
the presence of ATP. 
 
Figure 3.7. Control experiments. (a) Aptamer control: Frequency spectra obtained from a 
mixture of ctrl-MNPs and linker-MNPs with (red circle) and without (black square) 10 




and linker-MNPs without (black square) and with ATP (red circle), CTP (blue triangle), 
GTP (green diamond) or UTP (pink pentagon) at 500 µM. 
 
Quantitative Detection of ATP. Several experiments were carried out to 
evaluate the ability of the aptasensor to quantitatively measure ATP. Frequency spectra 
were obtained by the pre-incubation of apt-MNPs (1 mg/ml) with ATP at varying 
concentrations, (cATP, 0-10 mM) followed by the addition of linker-MNPs (1 mg/ml). For 
a detailed interpretation of the signals, the spectra were divided into two regions (low- 
and high-frequency regions) with peaks representing the clustered and single MNPs, 
respectively. We had the following observations of the frequencies and magnitudes of the 
peaks in the two regions with changing cATP:  
(1) Low-f region in Figure 3.8a and b: The magnitude of the negative peak at 0.47 
Hz was observed to decrease upon increasing cATP, meaning that more ATP resulted in 
fewer large clusters. The formation of large clusters was significantly impeded by high 
aptamer-occupancies for cATP ≥ 500 M. The magnitude of the positive peak at 2.67 Hz 
decreased with increasing cATP for cATP ≥ 500 M, suggesting that even the formation of 
intermediate-sized clusters was gradually hindered in this concentration regime. 
Additionally, the position shift of the positive peak with cATP may be due to that the peak 
was interwoven with the negative peak in the low-f region.   
 (2) High-f region in Figure 3.8a and c: Upon increasing cATP, the magnitude of 
the negative peak at about 127 Hz attributed to single MNPs increased. This indicates 
that more ATP resulted in higher aptamer occupancies, hence impeding the agglutination 




By comprehensively examining the above qualitative observations, we 
demonstrated that the degree of MNP clustering strongly depends on the ATP 
concentration in a sample and is consistent with the presented interpretation. 
 
Figure 3.8. (a) Frequency spectra obtained for ATP detection at varying concentrations, 
0-10 mM. The spectra are divided into two sections (low- and high-f regions) shown in 
magnified views in (b) and (c), respectively. Red arrows indicate the changes of the 
spectra for increasing ATP concentration. (d) Relative signal fraction Rfree from free 
MNPs as a function of ATP concentration. The red solid line shows the blank signal plus 





We further quantified the measured frequency spectra to obtain a calibration 
curve relating the degree of MNP clustering to the ATP concentration. To simplify the 
quantitative analysis from the fact that clusters of a variety of sizes co-exist in a sample, 
we assumed that the intensity integrals of the peaks in low- and high-f regions were 
proportional to the amount of clustered and single MNPs, respectively. We then defined 
the relative fraction of the signal from free MNPs to the total signal, Rfree, as (3.1). 








            (3.1) 
Applying the quantification method to the frequency spectra in Figure 3.8a, we 
obtained a calibration curve plotting Rfree as a function of ATP concentration on a semi-
log scale. Rfree was found to monotonically increase for increasing ATP concentration 
(Figure 3.8d). For blank samples, we obtained Rfree = 0.037  0.005, where the 
uncertainty indicates one standard deviation. The horizontal red line in Figure 3.8d 
showed the signal from the blank sample plus 3 standard deviations, which determined 
the limit of detection (LOD) of the aptasensor as 74 M. We found the dynamic range of 
at least 2 orders of magnitude where Rfree depends linearly on log(cATP). It was noted that 
the clustering was not completely inhibited even at mM ATP levels, which may be 
attributed to that clusters formed during the random motion and collision between apt-
MNPs and linker-MNPs may not be disassembled by competitive ATP binding to 
aptamer because the MNPs were linked by multiple hybrids. The results demonstrate the 
potential of the aptasensor as a simple tool for measuring ATP concentrations in the 




triplicates of the experiment were larger for low concentrations because large clusters 
tend to sediment during an optomagnetic measurement in the readout configuration. 
 
3.5. Conclusion 
In this chapter, we have demonstrated an aptamer-based inhibitive MNP 
clustering assay for ATP via size-selective measurements of MNP clusters on an 
optomagnetic readout system. A simple aptamer-based inhibition mechanism was utilized 
for MNP clustering-based detection of ATP, wherein ATP binding to aptamers affected 
the degree of MNP clustering. The degree of MNP clustering was measured vs. ATP 
concentration using an optomagnetic readout, which collects the 2nd harmonic optical 
transmission signal vs. frequency of an applied magnetic field. The acquired frequency 
spectra offer information regarding cluster sizes and relative amounts from peak 
frequencies and magnitudes, respectively. The size-selective measurements, resolving 
signals in terms of respective particle sizes, enabled us to effectively relate optical signals 
to degrees of MNP clustering, from which ATP concentrations can be estimated. Finally, 
a calibration curve was acquired by further analyzing the spectra, demonstrating that the 
extent of MNP clustering strongly depends on the ATP concentration. Moreover, the 
optomagnetic readout setup was simplified and miniaturized by implementation with a 
compact and low-cost Blu-ray OPU. We conclude that the inhibitive MNP clustering 
assay on the Blu-ray assisted optomagnetic system can be further developed as a point-
of-care diagnostic device for detection of various low molecular weight biomarkers in 




Based on the proof-of-concept study using ATP as a model analyte in this chapter, 
the optomagnetic aptasensor can in the future be extended to enable detection of AVP or 
other low molecular weight analytes in human bodily fluids. To construct an AVP assay 
using the optomagnetic aptasensor, an existing DNA aptamer [112], or a new aptamer 
isolated specially for this purpose using microfluidic methods [113], could be used; such 
aptamers, unlike the Spiegelmer used throughout this thesis, are composed of natural 
nucleotides and hence would readily allow for the design of complementary sequences to 
implement the inhibition assay principle required by MNP clustering-based detection. 
Furthermore, because the magnetic-based signals are not susceptible to interference from 
the presence of other biological components in a sample, this approach should readily 
allow AVP measurements in human bodily fluids. Combining such AVP detection 
capabilities with its compact and low-cost readout instrumentation, the optomagnetic 




Chaper 4. A Surface-Enhanced Raman Spectroscopic 
Aptasensor Using Leaning Nanopillars 
The mass spectrometric and optomagnetic approaches of Chapter 2 and 3, while 
showing much promise, are still faced with significant challenges in reliable and 
reproducible detection of AVP at low picomolar concentrations as required in clinical 
care. In this chapter, we present an aptasensor that is based on surface-enhanced Raman 
spectroscopy (SERS) to enable such ultrasensitive AVP detection with improved 
reproducibility. In SERS, a substrate densely packed with leaning nanopillars, whose 
surface is functionalized with an aptamer specific to AVP, is used as a SERS-active 
substrate that transduces aptamer-AVP binding into greatly enhanced Raman signals, 
allowing sensitive and specific detection of AVP labeled with a Raman tag. A large spot-
to-spot variation in SERS signals is overcome by performing large area Raman mapping 
on the substrate, thus enabling reproducible quantification of AVP in the picomolar 
range, with improved statistical reliability. Additionally, to facilitate the substrate 
handling and experimental operation, the substrate is integrated into a microdevice with 
temperature control units. Using the microchip incorporating the nanopillar substrate, we 
finally demonstrate competition-based indirect measurement of unlabeled AVP, showing 
its potential applicability to clinical diagnostics.   
 
4.1. Introduction 
Surface-enhanced Raman spectroscopy (SERS) has been widely used as an 
analytical tool in biosensing applications [114-118] due to its powerful advantages 




providing ultrahigh sensitivity, with the potential for single-molecule detection, and 
featuring the specificity of Raman spectra based on the unique molecular fingerprinting 
information [119-124]. Nevertheless, the reliable quantification of biomolecules (e.g., 
DNA, peptides, and proteins) [125-130] using SERS has been hindered by poor 
uniformity and reproducibility of SERS-active nanostructured platforms [131-133]. 
Furthermore, lack of specific binding and spot-to-spot fluctuations in signal intensities 
[134, 135] impede the development of SERS-based biosensors for quantitative detection 
of biomolecules. 
To overcome the aforementioned challenges in SERS-based biomolecular 
quantification, we here develop a new approach using large area Raman mapping on a 
SERS-active substrate that is densely packed with aptamer-functionalized leaning 
nanopillars, thereby enabling specific and quantitative detection of low abundance 
analytes without any limitation on molecular sizes. Large area Raman mapping on a 
substrate with uniformly distributed nanostructures allows reliable SERS quantification 
with improved reproducibility, accounting for spot-to-spot signal intensity fluctuation, a 
major drawback in conventional SERS quantification. In addition, microfluidic 
integration of the SERS-active substrate allows the entire procedure (e.g., biochemical 
surface functionalization, sample incubation, and surface washing) to be performed in an 
integrated manner without manual handling of the substrate, with minimized reagent 
volume. By applying this approach to the detection of AVP, we obtain concentration-
dependent responses in the picomolar range (1-1000 pM) when AVP is labeled with a 




measurement of label-free AVP, showing great potential of the aptasensor for detection 
of AVP at picomolar concentrations in clinical settings.   
 
4.2. Principle, Design, and Fabrication 
4.2.1. Principle 
Figure 4.1 illustrates the basic principle of SERS-based detection of AVP on 
aptamer-functionalized nanopillars. An AVP-specific aptamer is first immobilized onto 
the gold (Au) surface of silicon (Si) nanopillars via gold-thiol covalent bonding to 
selectively recognize AVP molecules (Figure 4.1a). To deliver amplified signals, a 
Raman signal reporter molecule, 5-carboxytetramethylrhodamine (TAMRA) is labeled to 
AVP, consequently TAMRA-labeled AVP (TVP) is the analyte in quantitative SERS 
analysis. The aptamer-functionalized nanopillar substrate is incubated with a TVP sample 
solution at 37 °C, the optimal temperature for aptamer-AVP binding (Figure 4.1b). After 
sequential washing steps using a buffer solution and purified water to remove 
nonspecifically adsorbed impurities and salt residuals respectively, the wetted substrate is 
allowed to completely dry (Figure 4.1c) for following Raman spectroscopy. Due to the 
surface tension between nanopillars during liquid evaporation [136], the nanopillars lean 
towards each other, forming micro-sized clusters and inducing near-field coupling effects 
between electronic excitations on gold surfaces of nanopillars known as localized surface 
plasmons (LSPs). In small metallic junctions (less than 10 nm) between adjacent 
nanostructures, the coupling effect of LSPs produces even larger plasmonic fields, so-
called hotspots (Figure 4.1d) [137-139]. Raman scattering of the incident light from 




modes. Since the inter-pillar distances after liquid evaporation are clearly less than 10 nm 
(Figure 4.1f), TVP molecules trapped within these clusters exhibit a pronounced Raman 
scattering signal from TAMRA tags even with a small number of molecules.  
 
Figure 4.1. Principle of SERS-based AVP detection on aptamer-functionalized leaning 
nanopillars. Schematic representation of aptamer-functionalized leaning nanopillar-based 
AVP detection: (a) aptamer-functionalized nanopillars; (b) sample incubation for 
aptamer-TVP binding at 37 °C; (c) surface tension force is applied to the nanopillars 
while the substrate is being dried; (d) the generation of SERS hotspot by leaning 
nanopillars. SEM images of (e) vertically standing before liquid contact and (f) leaning 






A microfluidic device integrating the aptamer-functionalized SERS-active 
substrate is shown in Figure 4.2. The SERS-active substrate incorporates gold (Au) 
coated silicon (Si) nanopillars (width: 50-80 nm; height: 600-800 nm), with the highest 
obtainable density (~20 pillars/µm
2
) to maximize the SERS signal based on the previous 
study which revealed that as the pillar density increases, the SERS signal increases in an 
exponential fashion [140]. The high uniformity of the nanostructure distribution over a 
substrate minimizes the variation within a scanning area on which the Raman mapping is 
performed. A diced substrate (3 mm × 3 mm) is inserted into a microdevice that consists 
of a polymeric reaction chamber (volume: ~ 10 µl) with an inlet and an outlet, a resistive 
microheater and temperature sensor (Cr/Au) integrated on the bottom glass substrate, a 
top PDMS-passivated glass window for leakage prevention and PMMA frames to hold 
the device together (Figure 4.2a and b). For the specific detection of biomolecules, 
aptamer molecules are immobilized on a gold surface of nanopillar structures via gold-
thiol covalent bonding. In addition, a monolayer of 6-mercapto-1-hexanol (MCH) spacer 
molecules is self-assembled onto the gold surface to prevent non-specific adsorption of 
molecules and to improve the capturing efficiency of the aptamer. Consequently, the 
surface functionalization helps analyte molecules to be uniformly distributed over the 
substrate area. Also, an electron beam evaporation process was developed to coat the 
silicon pillars with gold, such that the metallization thickness (~30 nm) was optimized for 
a laser excitation wavelength of 633 nm. The metal deposition on the pillar heads resulted 
in oval-shaped gold clusters (Figure 4.1e), which can be approximated as an ellipsoid or 





Figure 4.2. (a) A schematic and (b) a photo of the microdevice incorporating a nanopillar 
substrate (scale bar = 10 mm). (c) A SEM image of SERS-active nanopillars integrated in 
the device (scale bar = 2 µm). 
 
4.2.3. Fabrication 
Substrate Fabrication. Gold-coated silicon nanopillar structures developed by 
co-workers at Technical University of Denmark (DTU) were fabricated by maskless 
reactive ion etching of a silicon wafer followed by electron beam evaporation for gold 
deposition. Specifically, the nanostructured pattern was created on an undoped polished 
<100> silicon wafer surface with free standing vertical silicon pillars of 50-80 nm width. 
High-density nanopillars were formed using a reactive ion etching (RIE) method without 




for 1 min to completely remove the etchant gas residuals and the decomposition products. 
Finally, gold with a thickness of 30 nm was deposited on the heads of the nanopillars by 
electron beam evaporation to obtain the plasmonic property needed for SERS 
enhancement. Its simple and fine-tuned nanofabrication processes ensure reproducible 
production of substrates, which was demonstrated in their previous work [140].  
Microfluidic Device Fabrication. The microfluidic device consists of a substrate 
mounting hole (layer 1), a chamber and microchannels to inlet and outlet (layer 2), a 
glass substrate integrating a patterned microheater and temperature sensor, a glass 
window and plastic frames. To fabricate the layer 2, a layer of SU-8 was spin-coated onto 
a cleaned silicon wafer followed by UV exposure-initiated cross linking and baking steps. 
polydimethylsiloxane PDMS pre-polymer (Sylgard 184, Dow Corning) was then poured 
onto the mold and baked for 1 hr at 75 °C. The microstructured PDMS layer was then 
peeled off from the mold (Figure 4.3a), and was then punched through to make an open 
chamber in the center of the layer. In the meantime, the layer 1 was simply fabricated by 
pouring and baking PDMS on a bare silicon wafer, and was peeled off followed by 
punching through to allow the substrate insertion. Chrome (Cr, thickness: 5 nm) and gold 
(Au, thickness: 150 nm) layers were consecutively deposited on a cleaned glass substrate 
by thermal evaporation. Following the photolithographic patterning of the metal layers, 
the substrate was passivated with a thin PDMS layer using spin coating (Figure 4.3b). For 
packaging the device (Figure 4.3c), the layer 1 and 2 were bonded onto the substrate 
sequentially via oxygen plasma surface treatment. After the substrate was placed in the 




layer 2. Poly-methyl methacrylate (PMMA)-based plastic frames were used to hold the 
stack together, preventing liquid leakage.   
 
Figure 4.3. Fabrication and packaging of the device. (a) Fabrication of a PDMS layer 2 
using soft lithography with a SU-8 mold. (b) Micro-patterning of a metallic bilayer 
(Cr/Au) on a glass substrate using photolithography for a resistive microheater and a 
temperature sensor. (c) Packaging of the microdevice by bonding PDMS layers 
(passivation layer, layer 1 and 2) and inserting a diced SERS-active substrate.  
 
Surface Functionalization. The substrate was repeatedly cleaned with ethanol 
and deionized water rinsing. Aptamer solution (5 µM) was mixed with a stable reducing 
agent, TCEP (500 µM) for 30 min at pH 4 to expose the HS groups at the terminal of the 
aptamer sequences. PBS solution was added to the solution right before the substrate 




aptamer solution for 1 h followed by immersion in MCH solution (2 mM) for 2 h. After 
the functionalization, the substrate was rinsed with the mixture of 4 M urea and 15 mM 




AVP and 5-TAMRA labeled AVP (TVP) were obtained from American Peptide 
Company (Sunnyvale, CA). An AVP-specific aptamer (5’-GGG GUA GGG CUU GGA 
UGG GUA GUA CAC GUG UGC GUG GU-HS-3’), termed a Spiegelmer, was custom 
synthesized, and thiolated by ChemGenes Corporation (Wilmington, MA). A thiolated 
IgE-specific aptamer (5’-HS-TTT TTT TTG GGG CAC GTT TAT CCG TCC CTC CTA 
GTG GCG TGC CCC-3') was acquired from Integrated DNA Technologies, Inc. 
(Coralville, IA). Other chemicals used in buffer preparation and surface functionalization, 
TCEP (tris(2-carboxyethyl)phosphine hydrochloride), MCH (6-mercapto-1-hexanol), 
Tris-HCl, NaCl, KCl, CaCl2, MgCl2, urea, EDTA (ethylenediaminetetraacetic acid) and 
PBS (phosphate buffered saline, 1X), were all obtained from Sigma-Aldrich (St. Louis, 
MO). 
 
4.3.2. Experimental Setup and Procedure 
Experimental Protocol. Standard samples with TVP only or with TVP and AVP 
were prepared in binding buffer (pH 7.4) consisting of deionized water, Tris–HCl (20 
mM), NaCl (150 mM), KCl (5 mM), CaCl2 (1 mM), and MgCl2 (1mM). A sample 




nanopillars in the reaction chamber for 5 min while the chamber temperature was kept at 
37 °C using closed-loop temperature control. After the incubation, a buffer solution 
(volume: 100 µl; flow rate: 10 µl/ min) and purified water (volume: 20 µl; flow rate: 10 
µl/ min) was sequentially flushed through the chamber to remove unbound or non-
specifically adsorbed TVP molecules and salt residual, respectively. The substrate was 
then allowed to dry, forming leaning nanopillars, for subsequent Raman measurements.  
Raman Mapping Measurement. Raman mapping measurements were 
performed under the 632.8 nm excitation line of a He−Ne laser on an inVia Raman 
microscope (Renishaw, UK) in a standard backscattering configuration. The Raman 
signal was collected through a confocal pinhole of 25 μm diameter by using a 0.75 NA 
(numerical aperture) dry objective of ×50 magnification (Leica Microsystems, Germany). 
A computer controlled XY translation stage was used to acquire a total of 1000 SERS 
spectra within the scan area of 40 μm × 25 μm divided into an acquisition grid by 1 μm 
step size in both dimensions. All spectra in this work were obtained with an exposure 
time of 1 sec and at 0.3 mW laser power before the objective. The SERS intensity maps 




) were derived using the 
signal to baseline map generation algorithm of WiRE 3.2 software (Renishaw, UK) for 
spectral ranges of 1350-1390 cm
-1
 and 1490-1530 cm
-1
, respectively.  
Our experimental data were represented as intensity distributions to develop a 
theoretical model by expanding previously reported single-hotspot theory [141] to a 
large-scale SERS mapping model. The analytical model developed here has the potential 
to be used as a calibration curve in assay validation. Statistical tests between two heat 




mapping area required to unambiguously (at 95% confidence level) distinguish those two 
samples. Once the mapping area was calculated, multi-modal analysis, i.e., simultaneous 
monitoring of different frequency peaks, was also introduced as a useful tool to further 
reduce the overall assay time, maintaining statistical significance in analyte quantification 
measurements.  
 
4.4. Results and Discussion 
4.4.1. Characterization of Nanopillar Surface Functionalization 
Aptamer-Based Raman Signal Enhancement. We first investigated the effect 
of aptamer functionalization by comparing Raman spectra from untreated and aptamer-
functionalized substrates using manual signal acquisition. A substrate was incubated with 
a TVP sample solution (volume: 200 µl) in a tube for 1 hr, while the liquid temperature 
was maintained at 37 °C in a thermal-cycler (Eppendorf AG, Germany). The substrate 
was transferred into a buffer solution, and kept at 37 °C for 15 min to remove unbound 
molecules. Lastly, the substrates were quickly rinsed with water to remove salt residuals 
that induce the salt aggregation on a dried substrate. Four substrates at various conditions 
were prepared: (1) 10 µM TVP with untreated nanopillars, (2) 10 nM TVP with untreated 
nanopillars, (3) 10 nM TVP with aptamer-functionalized nanopillars, and (4) a blank 
sample with aptamer-functionalized nanopillars. As illustrated in Figure 4.4, the SERS 
signal from the aptamer-functionalized gold nanopillars (blue trace) treated with 10 nM 




 that can be 
assigned to the stretching vibrations of the xanthene ring moiety of the molecule [130, 




analysis. However, the spectrum of the same analyte concentration without aptamers 
(yellow trace) is comparable to the aptamer background (red trace) in which no 
significant peaks is observed. It can be concluded that the aptamer effectively captures 
TVP molecules, and helps positioning the analyte molecules close to the hotspots, 
referred to as aptamer-based Raman signal enhancement. Due to the SERS effect in the 
hotspot, the magnitude of peak intensities for the 10 nM TVP sample with aptamers (blue 
trace) were even higher than those of the 10 µM one without aptamers (green trace). We 
hypothesize that at µM concentrations the SERS effect is hindered by a thick layer of 
analyte molecules formed on top of the pillars, and the measured signal at 10 µM 






Figure 4.4. Raman spectra acquired on untreated and aptamer-functionalized substrates. 
When nonspecific adsorption of TVP on the substrate surface occurs (no aptamers), 
signal is only obtained at very high concentrations (10 μM TVP, green trace). At low 
concentrations (10 nM TVP, yellow trace) the signal enhancement is very low, indicating 
that very few molecules actually reside close to a hotspot. On the other hand, when the 
pillars are functionalized with an aptamer specific to AVP, the signal intensity greatly 





) of TAMRA were observed during experiments with different 
analyte concentrations. 
 
The Effect of Backfilling with MCH. In order to optimize the aptamer-analyte 




immediately after aptamer immobilization. Because MCH forms a well-organized self-
assembled monolayer (SAM), it prevents nonspecific adsorption of analyte molecules by 
blocking access to the gold surfaces [144-146]. This layer also improves the capture 
efficiency of the aptamers by preventing them from collapsing and adhering to the 
substrate surfaces [146, 147]. By comparing peak intensities obtained from two substrates 
functionalized with and without the MCH SAM, we were able to show that MCH is 
capable to reorient the thiolated aptamers into a vertical position favorable for aptamer-
analyte binding (Figure 4.5). 10 nM TVP samples were reacted with the two surfaces 
respectively. The result shows that the intensities from the surfaces functionalized with 
MCH are greater than those without for both diagnostic peaks, thus confirming that the 







Figure 4.5. The effect of 6-mercapto-1-hexanol (MCH) self-assembled monolayer (SAM) 
for aptamer-TVP binding. TVP molecules are bound on the aptamer-functionalized 
substrate (a) with and (b) without a monolayer of MCH. Due to the backfilling of MCH 
molecules, binding efficiency of aptamers is improved, and nonspecific adsorption of 
analyte is minimized. This effect is verified by experimental results shown in (c) and (d). 
The experiments were performed with 10 nM TVP samples on different substrates: 
aptamers with MCH layer (green), aptamers without MCH layer (red), and MCH only 
(blue). 
 
4.4.2. SERS-Based Quantitative Detection via Large Area Raman Mapping 
Large Area Raman Mapping. Several experiments with varying TVP 




quantify low-abundance molecules on the functionalized substrates. For each experiment, 
a large area of the substrate (101 µm × 33 µm) was scanned with 1 µm step size to collect 
Raman spectra from each pixel (1 µm × 1 µm). Recorded signals over the area were then 
displayed as heat maps rendering intensities by degrees of color. Mapping measurements 
were performed with three independent substrates at each concentration. The intensities 




) were extracted 
independently, and their spatial dependencies (Raman maps) were displayed in the format 
of pixel-based images at various TVP concentrations (Figure 4.6).  For each measurement, 
all positive intensities were ranked, and the hotspots were defined as the top 20% among 
such set of measurements. This percentage threshold was chosen based on the Pareto 
principle [148, 149]. Our experimental results showed that the higher the analyte 
concentration, the more abundant and brighter hotspots were detected for both frequency 
peaks, visually represented as heat maps (Figure 4.6a and b), and graphically as 








Figure 4.6. Large area Raman mapping of SERS intensity distribution. (a, b) Intensity 
maps of diagnostics TAMRA peaks 1370 cm
-1
 (left) and 1510 cm
-1
 (right) in a series of 
mapping experiments for quantification of intensities with 1 nM, 100 pM, 10 pM, and 1 
pM TVP. A substrate area of about 101 μm × 33 μm is shown in each case, along with 
the two intensity scale bars labeled with the maximum intensity values (in arbitrary units) 
for each diagnostic peak. The inset highlights a 1 µm
2 
area, which corresponds to a 
typical cluster of leaning nanopillars forming hotspots. The Raman map pixel size is 1 




different concentrations of TVP. Four histograms are displayed in overlaid configuration 
for both TAMRA dominant peaks, (a) 1370 cm
-1
 and (b) 1510 cm
-1
, corresponding to 
various analyte concentrations.  
 
Quantitative Raman Mapping Analysis. For quantitative analysis of each peak, 
peak intensities from hotspots (top 20 % of all the positive values) were integrated and 
plotted as a function of TVP concentration (Figure 4.7). To further understand the 
relationship between integrated signal intensities and analyte concentrations, we here 
developed a theoretical model as described follows. Histograms constructed for both 
diagnostic peaks and different TVP concentrations (Figure 4.6c and d) are observed to 
follow a highly skewed or long-tailed truncated Pareto distribution (TPD), with 
coefficient of determination values greater than 0.95. TPDs have previously been 
discovered to describe the intensity distribution characteristics of closely spaced SERS 
hotspots [135]. Since our experimentally obtained hotspot intensity distribution fits the 
predicted long-tailed TPD well, we can adapt an analytical framework for single hotspot 
theory [141] into our large-scale SERS mapping model. Now, by arbitrarily defining 
α=1+k, we can rewrite the intensity distribution function for a given analyte 
concentration (C) as:  
                                        𝑑(𝐼) ≈ 𝐴𝐶𝐼
−𝛼𝐶                                                       (4.1) 
where parameters α and A can depend on the analyte concentration. In particular, α 
determines how fast the enhancement decreases when moving away from the hotspot, 
while A is an indicator of how probable it is for a molecule to be located close to the 




substrate [141]. We observed that for both diagnostic peaks there is a strong power 
relationship between the experimentally obtained parameters, α and A, and the analyte 
concentration, C. Now, since both α and A are a power function of the analyte 
concentration, we have general forms. 
                                    𝛼(𝐶) = 𝑏𝐶𝑑               𝐴(𝐶) = 𝑒𝐶𝑓                       (4.2) 
where b, d, e and f are constants whose values are determined by the power fitting. 
Subsequently, we can express the hotspot intensity distribution analytically as a function 
of concentration by substituting (4.2) into (4.1). Then, the integral of the intensity 
distribution between the minimum (Imin) and maximum (Imax) intensity values gives the 
sum of all hotspot intensities (Isum) in a given mapping experiment. This integral can be 
expressed as a function of analyte concentration (C) such that: 
𝐼𝑠𝑢𝑚 = ∫ 𝑑(𝐼)
𝐼𝑚𝑎𝑥
𝐼𝑚𝑖𝑛
𝑑𝐼 = ∫ 𝐴(𝐶)𝐼−𝛼(𝐶)
𝐼𝑚𝑎𝑥
𝐼𝑚𝑖𝑛
𝑑𝐼 = 𝐴(𝐶) ∫ 𝐼−𝛼(𝐶)
𝐼𝑚𝑎𝑥
𝐼𝑚𝑖𝑛
𝑑𝐼            (4.3) 
By substituting (4.2) into (4.3), we obtain an analytical expression for the total 






1−𝑏𝐶𝑑]                    (4.4) 
This expression is believed to properly describe the collection of SERS signals 
measured on the uniform nanopillar substrates for different analyte concentrations. Figure 
4.7 shows the experimentally obtained intensity integrals of hotspots for both diagnostic 
peaks along with their respected power fit (black lines). The high coefficient of 
determination (R
2
) values (> 0.93) demonstrates a strong power relationship between 
TVP concentration and SERS intensity integrals. It is also observed that the 




calculated using the analytical expression shown in (4.4) with low percentage error 
values. The theoretical model is found to be more accurate for the 1370 cm
-1
 peak, with 
R
2
 value of 0.98. The fitting for the 1510 cm
-1
 peak is believed to be less accurate due to 
the broader shape of the band associated with this vibrational frequency, compared to the 
sharper 1370 cm
-1
 peak. The result shows that the analytical model developed here agrees 
with the experimental data, particularly well in the low concentration regimes. Thus, it 
can potentially be utilized to predict experimental hotspot intensity distributions on the 
substrate for quantitative measurements of low-abundance biomolecules. 
 
Figure 4.7. Experimental hotspot intensity integral plots for the diagnostic TVP peaks, (a) 
1370 cm
-1
 and (b) 1510 cm
-1
, as a function of analyte concentration on a semi-log scale 
(dotted curves). The error bars represent 2 standard deviations. Both curves fit power 
functions (solid black lines). The red curves are calculated from the hotspot intensity 
distribution of mapping experiments using the statistical model of equation (4.4). 
 
4.4.3. Control Experiments 
Aptamer Controls. Several control experiments were performed to confirm the 




performed on substrates functionalized without aptamers and with a nonspecific aptamer 
(immunoglobulin E (IgE)-specific aptamer) and compared with substrates functionalized 
with the AVP-specific aptamer; each substrate was reacted with 1 nM TVP sample. 
Using the Raman mapping on the substrate, 1000 spectra were collected at each condition 
and top 20% of the SERS signals at each diagnostic TAMRA peak were integrated and 
averaged for intensity comparison. Our results (Figure 4.8a) demonstrated that substrates 
functionalized with AVP-specific aptamers have superior specificity to TVP to the others. 
Signals from two control substrates could be attributed to nonspecific adsorption to 
surfaces and electrostatic attraction to charged DNA strands.  
Analyte Controls. Competition-induced analyte-dependent controls were 
compared between samples with TVP only, TVP with VP (unlabeled AVP which induces 
competition binding to AVP-specific aptamer with TVP) and TVP with DVP (D-
enantiomer of VP which has little affinity to the AVP-specific aptamer, which minimally 
interfere with TVP-aptamer binding). The results (Figure 4.8b) showed that the SERS 
signals from TVP were suppressed only when the sample includes VP, implying that 
TVP-aptamer binding must be competed with VP-aptamer one. 
 
Figure 4.8. Experimental results for various controls are shown. (a) Surface 
























Blank IgE aptamer Vasopressin aptamer


























TVP only TVP + VP TVP + DVP





aptamer (light grey) and with nonspecific aptamers (dark grey) / specific aptamers (black). 
(b) Competition-induced analyte-dependent controls were tested for 3 samples, TVP only 
(dark blue), TVP with VP (light blue) and TVP with DVP (blue). Analyte concentration 
is constant at 1 nM for all control experiments. 
 
4.4.4. Determination of Minimum Mapping Area 
Next, we aim to determine the statistically significant minimum mapping area 
required to unambiguously distinguish between treatment and control samples. The p-
values from KS (Kolmogorov–Smirnov) tests were calculated comparing a collection of 
SERS signals measured on two substrates treated with 1 nM TVP samples, each 
functionalized with AVP-specific aptamers and with IgE-specific aptamers respectively. 
Figure 4.9 indicates that when using the one-dimensional KS test (1d-KS) in which each 
peak is independently investigated, a total of 838 and 539 pixels are required to reach the 
p-value threshold (p = 0.05) for the 1370 cm
-1
 and 1510 cm
-1
 peaks respectively (Figure 






Figure 4.9. Advantages of combined sensory readings using the two-sample 2d 
Kolmogorov–Smirnov test. P-values of the KS test as a function of μm
2
 area (number of 
pixels) collected from heat maps based on the comparison of IgE-specific aptamer 
(control) and AVP-specific aptamer (treatment) data sets at 1 nM concentration. Hotspot 
intensity maps obtained for diagnostic TVP peaks, (a) 1370 cm
-1
 and (b) 1510 cm
-1
, in the 
treatment experiments. The insets show a green (1370 cm
-1
), orange (1510 cm
-1
) and 
yellow (combined) rectangular area, which correspond to unit areas determined by the 
KS tests. (c) 1d-KS test for diagnostic frequency of 1370 cm
-1
, (d) 1510 cm
-1 
and (e) 2d-





Unit area intensity plots corresponding to individual peaks (f) 1370 cm
-1
, (g) 1510 cm
-1
 
and (h) the combined multi-modal analysis as a function of analyte concentration on a 




for the same concentration and are all less than 5% of measured data values. All curves 
fit power functions (solid red line). 
 
Furthermore the two-dimensional KS test (2d-KS) [150] was utilized to evaluate 
the effect of the combined multi-modal analysis. Using 2d-KS test in which the two 




) were evaluated simultaneously, only 
209 pixels were needed to be 95% confident that the treatment is distinguishable from the 
control (Figure 4.9e). These results suggest that the combined multi-modal sensory 
analysis outperforms the analysis where just one frequency shift is used. Using 1 s 
exposure time during acquisition, the mapping time can be reduced from 10-15 minutes 
(539-838 pixels) to less than 4 minutes (209 pixels) by applying the multi-modal analysis. 
Thus, this SERS mapping technique has great potential to be integrated into a rapid 
bioassay. Figure 4.9 also shows the intensities of hotspots obtained for various analyte 
concentrations per unit area, where the unit area is defined as the statistically significant 
minimum mapping area (Figure 4.9f-h). The intensities per unit area averaged over 100 
randomly selected unit areas are presented for both individual peak analysis (Figure 4.9f 
and g) and the combined multi-modal analysis (Figure 4.9h) along with their respected 
power fit (solid red lines). Both analyses show concentration-dependent SERS intensity 
integrals over the unit area in the sub-nanomolar range.  The error bars are less than 5% 
of the measured data for all analyses. Similarly to the theoretically derived equation (4) to 
fit the experimental data, the high experimental R
2
 values (> 0.95) indicate a strong 
power relationship between the unit area intensity and the TVP concentration as shown in 




any observable change in final SERS result. The multi-modal analysis allows one to 
significantly reduce time to perform a reliable and statistically significant analyte 
quantification experiment. 
 
4.4.5. AVP Detection in a Microfluidic SERS Aptasensor  
Based on the characterization results in previous sections (Section 3.4.1-3.4.4), 
which determined the optimal surface functionalization condition and mapping area, the 
AVP detection within our microfluidic SERS aptasensor was tested following the 
experimental protocol presented in Section 3.3.2.     
TVP Detection. To first demonstrate the ability to quantitatively measure TVP 
using our device, several experiments were performed at varied concentrations (10-200 
pM). As the concentration increases, more and brighter signals were detected for both 
peaks (Figure 4.10a and b). It was also observed that the intensity integrals of SERS 
signals for both peaks were linearly proportional to TVP concentrations in this low 
picomolar range (Figure 4.10c and d). The calibration curves in the regime confirm the 
concentration-dependent SERS response behavior of our aptasensor, demonstrating that 
our approach is suitable for the quantitative measurement of such a low molecular weight 





Figure 4.10. Heatmaps at various concentrations (10/ 50/ 100/ 200 pM) for 1370 cm-1 (a) 
and 1510 cm-1(b) peaks. Calibration curves for 1370 cm-1 (c) and 1510 cm-1 (d) peaks. 
 
Label-Free AVP Detection. Finally, quantitative analysis of label-free AVP 
molecules was attempted via competition binding assay between unlabeled AVP and 




and 100 nM. While the TVP concentration was kept at 10 nM for all the experiments, the 
concentration of AVP was varied from 1 nM to 100 nM. As can be seen in Figure 4.11, 
the intensity integral of SERS signals from TVP decreases as the AVP concentration 
increases, which could be attributed to that TVP binding to the aptamer were impeded by 
the presence of AVP based on competitive binding principle. In particular, more 
distinguishable signals for both peaks were detected between 1 nM and 10 nM, indicating 
that the dynamic range of the assay resides in the regime. These results demonstrate the 
potential utility of our microfluidic SERS aptasensor as a quantitative assay for naturally 
occurring AVP. Label-free detection of AVP at picomolar levels was not achieved (data 
not shown) because of inherently lowered detection sensitivity on a competitive binding 
assay format.   
 
Figure 4.11. Experimental results for the quantitative detection of unlabeled AVP using 
SERS-based competition binding assay for 1370 cm-1 (a) and 1510 cm-1(b) peaks. TVP 






In this chapter, we have demonstrated a SERS-based quantitative detection of 
AVP on aptamer-functionalized nanopillars, integrated into a microfluidic system, 
utilizing large area Raman mapping technique. Highly-sensitive and specific detection of 
TAMRA-labeled AVP (TVP) was achieved at picomolar levels by collecting 
significantly enhanced Raman signals emanating from nano-junctions formed between 
the leaning nanopillars and functionalizing surfaces with target-specific aptamers. 
Statistical reliability and reproducibility of quantitative SERS analysis were improved by 
large area Raman mapping on the highly uniform substrates. Based on our experimental 
mapping results, we successfully developed a theoretical model to be utilized as an 
analytical tool for biomolecular quantification on the aptamer-functionalized nanopillar 
substrates. Furthermore, for the assay optimization, we determined the minimum size of 
mapping area providing statistical reliability by applying a KS test between treatment and 
control data. Finally, by employing a competitive binding assay configuration, we 
showed that one can measure label-free AVP in the nanomolar range (1-100 nM) using 
the microfluidic SERS aptasensor, and we believe that our approach is a promising 
technique for specific and sensitive detection of AVP in clinical diagnostics. 
In the future, a more practically viable biosensor system could be produced by 
microfluidic integration of in-situ Raman tag labeling with SERS-based aptasensing. For 
example, in-situ labeling could be achieved by incubating NHS-terminated TAMRA with 
AVP on aptamer-functionalized microbeads within a microchamber. The reaction 
between NHS ester and amine within AVP results in TAMRA-labeled AVP (TVP), and 
TVP molecules bind to aptamer on microbead surfaces. After the removal of unreacted 




TVP interacts with the aptamer on leaning nanopillars and is analyzed by large area 
Raman mapping as described above. The effects of interference from biological 
impurities on the detection sensitivity and reproducibility could also be addressed by 
either concentrating AVP during or prior to the in-situ labeling step (as described in 
Section 2.4.3.), suitably enlarging a map size in Raman mapping, or combining both of 
these methods. Such a totally integrated system would ultimately enable ultrasensitive 
detection of endogenous AVP at low picomolar concentrations from human patient 





Chaper 5. An Integrated Aptasensor Combining Aptamer-
Based Preconcentration and Graphene Nanosensing 
In this chapter, we present a graphene-based aptasensor that achieves sensitive 
detection of AVP at clinically relevant picomolar concentrations without the labeling of 
the analyte. This label-free device, which complements the sample labeling-based SERS 
aptasensor presented in Chapter 4, combines aptamer-based selective analyte 
preconcentration, isocratic elution and conductance-based graphene nanosensing within a 
microfluidic device. An AVP-specific aptamer specific is immobilized on microbeads for 
selective preconcentration and isocratic elution of the analyte. A conductance-based 
graphene nanosensor using a competitive assay format achieves rapid, label-free 
detection, with a high sensitivity due to surface binding-induced changes in carrier 
concentration in the bulk of graphene. Microfluidic integration of analyte 
preconcentration and graphene nanosensing on a single chip eliminates the need for off-
chip sample handling, thus minimizing potential sample contamination or loss. 
Experimental results show that our device is capable of detecting label-free AVP at 
clinically relevant picomolar levels (1-500 pM).   
   
5.1. Introduction 
Graphene is a one-atom thick nanomaterial consisting of carbon atoms arranged 
as a two-dimensional (2D) hexagonal crystalline form, first reported in 2004 [151]. The 
monoatomic structure of graphene offers unique physical properties such as high 
mechanical strength and flexibility [152], excellent thermal [153] and electrical [154] 




carriers confined within an atomically thin layer, graphene exhibits high carrier mobility, 
fast saturation and low charge scattering [156, 157]. Owing to these properties and the 
large surface-area-to-volume ratio [158], graphene has been used in various biosensors 
(e.g., electrochemical [159-161], optical [162-164], and plasmonic [165, 166]). In 
particular, conductance-based graphene biosensors using a field-effect transistor (FET) 
configuration [167-169] have received increasing attention because of their simple 
designs, rapid and sensitive detection capabilities, and low-cost implementation. Notably, 
due to the fact that every carbon atom is located on the graphene surface with its two-
dimensional structure, molecular binding to the surface induces changes in carrier 
concentration in the bulk of graphene, enabling sensitive conductance-based detection of 
analytes.        
For specific analyte detection in conductance-based sensing scheme, graphene has 
been functionalized with molecular probes, such as antibodies [170, 171] or aptamers 
[168, 172]. However, their applicability is still limited to macromolecules (e.g., protein, 
and nucleic acids) with high electrical charge, while the development of conductance-
based graphene biosensors for detection oligopeptides and small molecules is particularly 
challenging as the weakly-charged molecular binding does not directly induce detectable 
changes in graphene conductivity.   
We here present an integrated microfluidic aptasensor which combines aptamer-
based specific preconcentration and conductance-based graphene nanosensing, allowing 
highly sensitive detection of a low charged oligopeptide target. An aptamer specific to a 
target analyte is immobilized on microbeads for solid phase-based selective 




configuration is used to measure changes in graphene conductance, related to the analyte 
concentration. Microfluidic integration of analyte preconcentration and detection on a 
single chip eliminates the need for off-chip sample handling, thus minimizing potential 
sample contamination or loss. Experimental results show that our integrated aptasensor is 
capable of detecting label-free AVP at clinically relevant low concentrations (1-500 pM), 
demonstrating its great promise as a clinical AVP assay. 
 
5.2. Principle, Design, and Fabrication 
5.2.1. Principle 
The principle of AVP detection in our device is schematically shown in Figure 5.1.  
Aptamer-Based Selective Preconcentration. AVP molecules in a sample 
solution (“sample AVP”) are selectively captured and enriched on microbead surfaces via 
affinity binding to the surface-immobilized aptamer (Figure 5.1a) during continuous 
sample infusion into the device at 37 °C. After the removal of nonspecifically adsorbed 
AVP molecules and impurities through buffer washing (Figure 5.1b), the concentrated 
AVP molecules are released into an eluent containing solution-borne aptamer molecules 
(“free aptamer”) by thermally-induced disruption of aptamer-AVP complexes at 55 °C 
(Figure 5.1c).  
Aptamer-Based Competitive Assay on Graphene. The eluate, a mixture of the 
free aptamer and released AVP originally captured from the sample (“sample AVP”), is 
then incubated with graphene pre-functionalized with reagent AVP (“standard AVP”) at 
37 °C (Figure 5.1d). The graphene-bound standard AVP competes with the solution-




increase in the charge on the graphene (Figure 5.1e). Hence, more sample AVP eluted in 
a mixture results in less aptamer molecules bound on the graphene surface, inducing 
smaller changes in graphene conductivity. 
 
Figure 5.1. Principle of AVP detection. Sample AVP is enriched on microbead surfaces 
by aptamer binding (a). After the buffer washing (b), the temperature is raised to 55 °C, 
which disrupts aptamer-AVP complexes and release sample AVP into a free aptamer 
solution (c). The mixture of the free aptamer and released sample AVP is incubated with 
graphene functionalized with standard AVP (d), inducing the binding of the free aptamer 
to the  standard AVP on graphene via competitive binding (e), thus changing the 





Conductance-Based Graphene Nanosensing. For the measurement of changes 
in graphene conductivity, we employ a FET configuration in which graphene serves as a 
conducting channel. In aqueous media, molecular binding on the graphene surface creates 
a self-assembled monolayer (SAM) and forms an electrical double layer (EDL), which is 
a thin layer at the interface of an electrolyte solution and a charge surface in which 
counter ions dominate co-ions in concentration. Here, the EDL can be represented as a 
parallel-plate capacitor on the graphene surface, across which a top-gate voltage is 
applied and controls the carrier density and the electrical conductivity of graphene. Since 
the free aptamer is highly charged oligonucleotides, its adsorption generates changes in 




As shown in Figure 5.2, our integrated microdevice consists of a preconcentration 
microchamber (height: 200 µm, volume: 2.5 µl), a graphene-based sensing microchamber 
(height: 1 mm, volume: ~5 µl) combined with a graphene nanosensor, three temperature 
control units (Cr/Au resistive microheater and temperature sensor), and a flow gate 
connected to a serpentine channel (width: 500 µm, height: 20 µm) for sample transfer to 
the sensing microchamber. A weir structure (height: 20 µm) in the preconcentration 
microchamber retains microbeads (diameter: 50 to 80 µm) within the chamber during the 
selective preconcentration process. Three sets of a resistive heater and a temperature 
sensor separately control temperatures inside two microchambers and the serpentine 





Figure 5.2. (a) Schematics and (b) a photo of the device. (c) Demonstration of flow 
gating. By plugging the waste outlet, a fluorescein solution is guided to the graphene 
sensing chamber. 
 
A graphene nanosensor of a FET configuration is shown in Figure 5.3. The source 
and drain electrodes are connected by a graphene conducting channel. A top-gate voltage 
is applied on the gate electrode forming a top-gate voltage (Vgs) through a sample 
solution. In this standard FET configuration, the electric conductance of graphene, which 
depends on the charge on the graphene surface, was measured from the drain current (Ids) 





Figure 5.3. (a) A schematic and (b) a micrograph of the graphene nanosensor. 
 
5.2.3. Fabrication 
The integrated microdevice was fabricated of a polydimethylsiloxane (PDMS) 
microfluidic layer bonded onto a glass substrate integrated with a resistive microheater 
and sensor via standard microfabrication processes such as photolithography and soft 
lithography (Figure 5.4). To prepare an SU-8 mold for the PDMS layer, a silicon wafer 
was cleaned by soaking in piranha solution (a mixture of 98% sulfuric acid and 30% 
hydrogen peroxide, 3:1, v/v) for 1 hour. The wafer was then rinsed with deionized water 
and baked at 150°C for 10 minutes. Two layers of SU-8 were spin-coated on the silicon 
wafer, exposed to ultraviolet (UV) light through photomasks to initiate polymer 
crosslinking. The wafer was immersed into a SU-8 developer solution to dissolve 
unexposed area and baked to define a mold for generating PDMS microstructures (Figure 
5.4a-c). PDMS pre-polymer (Sylgard 184, Dow Corning) was then spread onto the SU-8 
mold, cured at 75°C for 1 hour on a hotplate, and peeled off from the mold (Figure 5.4d). 
A thick PDMS piece was bonded onto the preconcentration microchamber region to 
allow stable inlet and outlet port connection to plastic tubes for sample handling 
following oxygen plasma treatment of the bonding surfaces (Figure 5.4e). In the 




consecutively deposited on a piranha cleaned glass substrate using a thermal evaporator 
(Auto 306, BOC Edwards). After the metal layers were patterned using positive 
photolithography (Figure 5.4g-i), they were passivated with a thin PDMS layer (thickness: 
20 μm) through spin coating (Figure 5.4j). After punching holes for inlets (Figure 5.4f), 
outlets and to allow a sensing chamber in the PDMS layer, it was bonded to the glass 
substrate via oxygen plasma surface treatment (Figure 5.4k). A syringe needle (gauge 26) 
was inserted through the side of the PDMS layer into the sensing microchamber, used as 
a sample outlet (Figure 5.4l). A prepared graphene FET substrate was then placed onto 
the sensing chamber and pressed by plastic holders to ensure complete sealing of the 





Figure 5.4. Fabrication processes of the integrated microdevice. 
 
The graphene-based FET was fabricated on a glass substrate [173]. CVD-
graphene was synthesized by heating annealed Cu foil in a quartz tubing furnace. The Cu 
foil was first sharply heated to 1000 °C in Argon (Ar) environment (200 mTorr), and 
annealed in hydrogen (H2) environment (10 mTorr). The mixture of methane (CH4) and 
H2 were then introduced and allowed to react for 18 min (CH4: 170 mTorr, H2: 10 mTorr), 
after which the sample was cooled down to room temperature in Ar flow at 200 mTorr 
and then retrieved from the tube. After graphene growth, 500nm polymethylmethacrylate 




pressing. Cu was removed by wet etching and graphene was transferred onto the substrate 
at 170 °C to realize the graphene conducting channel stretching over patterned 
drain/source electrodes on a glass substrate.  
For the AVP functionalization, graphene was first incubated for 1 h in a linker 
solution (2 mM PASE in methanol). PASE serves as a linker as its pyrenyl group was 
irreversibly attached to the basal plane of pristine graphene via π-π stacking. The 
graphene was then sequentially rinsed with methanol and PBS followed by the incubation 
in an AVP solution (1 μM in PBS) for 12 h. The amino group of AVP was conjugated 
with the linker as PASE releases N-hydroxysuccinimide (NHS) forming a stable amide 
bond. 100 mM ethanolamine was then incubated in the channel for 1 h to deactivate the 




AVP and TAMRA (5-carboxytetramethylrhodamine)-labeled AVP (TVP) were 
purchased from American Peptide Company Inc. (Sunnyvale, CA). An AVP-specific 
aptamer (5’-GGG GUA GGG CUU GGA UGG GUA GUA CAC GUG UGC GUG GU-
3’), i.e., Spiegelmer, and an ATP-specific aptamer (5’-ACC TGG GGG AGT ATT GCG 
GAG GAA GGT AAA AAA A-3’) were obtained from ChemGenes Corporation 
(Wilmington, MA) and Integrated DNA Technologies Inc. (Coralville, IA) respectively. 
Streptavidin-coated polyacrylamide beads were acquired from Thermo Fisher Scientific 
Inc. (Rockford, IL) and functionalized with aptamers via streptavidin-biotin links. Buffer 




mM), KCl (5 mM), CaCl2 (1 mM), MgCl2 (1mM) from Sigma-Aldrich (St. Louis, MO). 
Annealed Cu foil (99.8%, 25 μm thick) was purchased from Alfa Aesar (Ward Hill, MA) 
for CVD-graphene synthesis. 300 nm SiO2 coated Si wafer was obtained from Si-Tech 
(Topsfield, MA) for device substrate. PASE linker purchased from Life Technologies 
(Carlsbad, CA) 
 
5.3.2. Experimental Setup and Procedure 
The device was initially rinsed with buffer (10 µl/min), and the sensing 
microchamber was filled with a buffer solution to measure a reference signal (Ids,ref). A 
sample solution (10 µl/min for 2 hrs) prepared in buffer with varying AVP concentrations 
was continuously introduced into the preconcentration microchamber using a syringe 
pump (KD210P, KD Scientific Inc.) while the chamber was maintained at 37 °C using a 
temperature control unit (an integrated microheater and a temperature sensor controlled 
by LabVIEW) integrated on the bottom glass substrate. Following the preconcentration, 
the chamber was thoroughly rinsed with a buffer solution (10 µl/ min) at 37 °C. After the 
waste outlet was closed, a plug of the free aptamer solution at 25 nM was flowed through 
(10 µl at 10 µl/ min) the preconcentration microchamber at an elevated temperature, 
60 °C. The eluted mixture of enriched sample AVP molecules and free aptamer 
molecules was then transferred to the sensing microchamber whose temperature is kept at 
37 °C by activating the flow gate with the plugged waste outlet.  
The measurement circuit used a triple DC power supply (E3631A, Agilent) to 
provide the DC drain voltage Vds, a function generator (33220A, Agilent) to supply the 




current (Ids). Measurements were automatically controlled through a PC-based LabVIEW. 
During the electrical measurement, Ids values (at a fixed Vgs and Vds) were automatically 
collected once per second for a determined period. 
 
5.4. Results and Discussion 
5.4.1. Characterization of Graphene Nanosensing  
We first characterized the aptamer binding-induced change in graphene 
conductance using our graphene nanosensor. A free aptamer solution at different 
concentrations in the range of 0-1000 nM was incubated with the graphene nanosensor 
until Ids reached a saturated level. The magnitude of the conductance difference, δIds=|Ids-
Ids,ref|, was found to increase with the free aptamer concentration and saturate above 100 
nM, indicating that the increase of surface charge arises from the affinity binding of 
highly-charged nucleic acid aptamer molecules to standard AVP on the graphene surface 
(Figure 5.5). Least square fitting of a monovalent binding model to the experimental data 
yielded a dissociation constant (Kd) of 16.7 nM for aptamer-AVP binding, approximately 
10 times higher than the value previously obtained in solution (1.7 nM [73]), which could 
be attributed to the restriction of configurational freedom of surface-immobilized AVP, 
that substantially reduces their binding kinetics [98].  
To confirm the specificity of the aptamer-AVP binding, we also conducted 
control experiments with an ATP-specific aptamer (nonspecific to AVP) following the 
same protocol. δIds was found to be less than 1 µA, much smaller than its value with the 
AVP-specific aptamer and irrelevant to the aptamer concentration. This indicates that 




aptamer does not adsorb onto the graphene surface via aptamer-standard AVP binding, 
but nonspecifically adsorbs onto the graphene surface, confirming that our approach is 
highly specific to AVP.      
 
Figure 5.5. Characterization of the graphene nanosensor by measuring changes in 
graphene conductivity with varying free aptamer concentrations (0-1000 nM). 
Experiments were respectively conducted with AVP-specific free aptamer (test, black 
square) and ATP-specific free aptamer (control, blue diamond).  
   
The nanosensor was then tested with standard mixtures of the free aptamer at a 
fixed concentration (25 nM) and sample AVP at a varying concentration (cAVP, 1-100 
nM). Results showed that δIds decreased with increasing cAVP in the range of 1-100 nM, 
which is attributed to that a higher AVP concentration in a standard mixture causes a 
higher aptamer occupancy, which impeded the aptamer binding to surface-immobilized 
standard AVP (Figure 5.6). However, no appreciable variation in δIds with varying cAVP 




AVP prior to graphene nanosensing to achieve the AVP detection in the low picomolar 
range, required in clinical settings.    
 
Figure 5.6. Measurements with standard mixtures of free aptamer at 25 nM and sample 
AVP at varying concentrations (1-100 nM). 
 
5.4.2. Characterization of Aptamer-Based Selective Preconcentration 
To achieve AVP detection at picomolar levels, we here combine a selective 
analyte preconcentration, enabled by solid-phase aptamer-based recognition, with 
graphene nanosensing. We first characterized the aptamer-based selective 
preconcentration of AVP on microbead surfaces via fluorescence measurements. A 
TAMRA (as a fluorophore)-labeled AVP (TVP) solution at 100 pM was continuously 
infused into the preconcentration microchamber (10 μl/min) while the chamber 
temperature was maintained at 37 °C, and the fluorescence intensity of the bead surface 
was measured every 15 min. It was observed that mean fluorescence intensities increased 




infusion for more than 1.5 hr is needed to attain sufficient analyte preconcentration. The 
thermally activated release of captured AVP molecules was also tested by flushing beads 
with a free aptamer solution at 55 °C. The fluorescence intensity was quickly (< 1 min) 
dropped down to the baseline, indicating that enriched sample AVP molecules were 
released from aptamer at 55 °C which disrupts aptamer-AVP complexes. This 
temperature-dependent behavior of aptamer-AVP binding enables isocratic elution of the 
analyte, allowing subsequent graphene nanosensing. 
 
Figure 5.7. Fluorescence based time resolved measurements of aptamer-based specific 
preconcentration during continuous introduction of a 100 pM TAMRA-labeled AVP 
(TVP) solution at 37 °C, followed by infusing a free aptamer solution at 55 °C for 





5.4.3. AVP Detection 
To confirm the specificity of aptamer-based preconcentration of AVP, we tested 
integrated devices with and without aptamer on microbead surfaces for detection of AVP 
at 100 pM. Tests with the devices with bare-beads produced higher δIds values than those 
with aptamer-functionalized bead-packed devices (Figure 5.8). This indicates that the 
sample AVP was significantly enriched by repeated aptamer-based affinity binding on 
the bead surface, resulting in the higher sample AVP concentration in a mixture.  
 
Figure 5.8. Bead-control experiments. Integrated devices with and without aptamers on 
microbeads were tested with 100 pM AVP to verify the specificity of aptamer-based 
analyte preconcentration.  
 
We finally tested detection of AVP at clinically relevant picomolar concentrations 
(1-500 pM) using the integrated device. To account for experimental variability caused 




respect to δIds,max, i.e., the maximum conductance change of an individual graphene 
nanosensor. Experimental results showed that δIds decreased with increasing cAVP (Figure 
5.9), implying that a higher cAVP results in a higher aptamer occupancy in the mixture, 
thus less free aptamer molecules can bind to standard AVP on graphene. The results also 
confirmed the effectiveness of aptamer-based selective preconcentration by 
demonstrating the picomolar detection that was difficult to attain without the 
preconcentration process. It can thus be concluded that our approach is capable of 
quantitatively detecting AVP at picomolar levels, confirming the potential of our device 
as a quantitative AVP assay in clinical diagnostics. We speculate that the large error bars 
could arise from a variation of microbead packing density in the preconcentration 
microchamber between devices.        
 
 
Figure 5.9. Normalized signals obtained from experiments with varying sample AVP 






We have developed a microfluidic aptasensor for conductance-based graphene 
nanosensing of AVP with high sensitivity. The device integrates aptamer-based specific 
preconcentration and graphene nanosensing on a single chip, achieving label-free 
detection of low-abundance AVP. A bead-immobilized AVP-specific aptamer conducted 
the selective preconcentration of AVP molecules from a dilute sample, thus improving the 
detection sensitivity of the graphene nanosensor. After the analyte preconcentration, the 
AVP concentration was measured by graphene nanosensing via competitive aptamer 
binding between enriched sample AVP in solution and standard AVP immobilized on 
graphene. Following their individual characterization, the processes of aptamer-based 
preconcentration and graphene nanosensing were combined to enable quantitative 
detection of label-free AVP at clinically relevant concentrations (1-500 pM), showing its 
great potential as a clinical AVP assay.    
In the future, our device can be further extended to the detection of AVP from 
human bodily fluids. The fundamental concept of the microfluidic device should be 
readily applicable to such complex samples. The likely decrease in detection sensitivity 
and reproducibility, which may arise from low analyte abundance in bodily fluids with 
high biological complexity, could be addressed by optimizing the device design (e.g., 
shape and dimensions) and experimental protocols (e.g., infused sample volume and flow 
rate) to effect sufficient and selective preconcentration of endogenous AVP, thus 





Chaper 6. Concluding Remarks 
6.1. Summary of the Thesis 
In this thesis, we presented four different aptasensors for label-free and sensitive 
detection of low molecular weight analytes, addressing a major challenge facing existing 
aptasensing approaches that commonly require detailed and precise information on 
aptamer structures and binding characteristics. Our aptasensors utilized different micro- 
and nanomaterials, each of which provides unique properties such as high surface-area-
to-volume ratio, sensitivity, and low signal interference. Combined with nucleic acid 
aptamers as highly specific recognition elements, the micro- and nanodevices could 
selectively detect their target analytes in the concentration range of clinical importance. 
We first presented an integrated microfluidic aptasensor coupled to mass spectrometry, 
which demonstrated sensitive and label-free detection of arginine vasopressin (AVP), an 
oligopeptide hormone and a clinically important biomarker for prevention of late-phase 
hemorrhagic shock, from human plasma ultrafiltrate. We then introduced an 
optomagnetic aptasensor for detection of adenosine triphosphate (ATP) via magnetic 
nanoparticle clustering assay, which could be further adapted to AVP detection. Next, we 
presented a surface-enhanced Raman spectroscopic aptasensor which can specifically and 
reliably quantify AVP with high sensitivity. Lastly, we described a microfluidic 
aptasensor that integrates integrating aptamer-based selective preconcentration and 
graphene nanosensing on a single chip, demonstrating label-free and sensitive detection 
of AVP at clinically relevant picomolar levels.  
In Chapter 2, we presented an integrated microfluidic aptasensor for mass 




purification chamber of the integrated device, an aptamer specifically captured and 
enriched AVP on microbead surfaces via affinity binding. After bead washing steps with 
buffer and water sequentially, thermally-activated release of enriched AVP molecules 
enabled the collection of AVP in purified water. The purified AVP sample was then 
repeatedly deposited on a spot using a piezoelectric-driven nanoliter-droplet ejector in the 
device. Finally, the dried sample spot was analyzed by matrix-assisted laser desorption/ 
ionization time-of-flight (MALDI-TOF) mass spectrometry to determine the AVP level 
in an original sample. Experimental results demonstrated that our approach is capable of 
label-free mass spectrometric detection of AVP from human plasma ultrafiltrate samples 
at clinically relevant picomolar concentrations. 
In Chapter 3, we presented an optomagnetic aptasensor for detection of ATP 
using oligonucleotide-conjugated magnetic nanoparticles (MNPs). To determine the 
concentration of ATP from the degree of MNP clustering, we employed an inhibition 
assay configuration with two mutually exclusive binding reactions (aptamer-ATP binding 
and aptamer-linker DNA hybridization), where the aptamer and the linker were 
immobilized onto separate MNPs. Consequently, the ATP addition hindered the MNP 
clustering induced by aptamer-linker hybridization, thus enabling us to relate the degree 
of MNP clustering to the ATP concentration. The clustering state was measured using an 
optomagnetic readout system that provides information on the distribution of 
hydrodynamic sizes of MNP clusters. Using this technique, we demonstrated that the 
change of the optical response was well correlated with the ATP concentration in the 




Aiming to achieve reliable and reproducible detection of AVP at low picomolar 
concentrations, which was the aptasensors presented in Chapter 2 and 3, we introduced in 
Chapter 4 an aptasensor that uses surface-enhanced Raman spectroscopy (SERS) as an 
ultrasensitive detection technique. A SERS-active substrate bearing gold-decorated 
silicon nanopillars was functionalized with an aptamer for specific detection, and used for 
generating enhanced Raman signals through nanopillar leaning mechanism for sensitive 
detection. Large area Raman mapping ensured reliable quantification of AVP molecules 
adsorbed on the nanopillar surface via aptamer-based affinity binding. Microfluidic 
integration enabled efficient detection of the analyte, and competitive binding assay 
allowed label-free quantification of the analyte. Experimental results showed that our 
aptasensor could quantitatively measure Raman tag-labeled AVP in the picomolar range 
and unlabeled AVP in the nanomolar range.  
As a complementary approach to SERS which requires Raman tag labeling of 
AVP molecules in the sample to achieve picomolar sensitivities, graphene nanosensing 
was employed in an integrated aptasensor in Chapter 5. The integrated aptasensor 
combined aptamer-based selective preconcentration on microbeads and conductance-
based graphene nanosensing, allowing detection of a low-abundance analyte. An aptamer 
specific to AVP was immobilized on microbeads for selective preconcentration and 
isocratic elution of the analyte. A conductance-based graphene nanosensor using a 
competitive assay format achieved label-free detection, with a high sensitivity due to 
surface binding-induced changes in carrier concentration in the bulk of graphene. 
Microfluidic integration of selective preconcentration and graphene nanosensing on a 




sample contamination or loss. Experimental results showed that the graphene-based 
nanosensor could achieve detection of AVP at picomolar concentrations (1-500 pM) in a 
label-free manner, thus demonstrating its potential utility in clinical settings.  
 
6.2. Future Work 
This thesis research has demonstrated the development of micro and nanoscale 
aptasensors for detection of various low molecular weight analytes. In particular, we have 
identified SERS- and graphene-based aptasensors as highly promising to enable detection 
of AVP at clinically relevant low concentrations from human plasma ultrafiltrate. 
Therefore, future work will be focused on further improvement on these two aptasensing 
approaches using microfluidic technology.  
SERS-Based Aptasensor. To enable AVP detection by SERS in clinical 
diagnostics, a more practically viable biosensor system could be developed by combining 
in-situ Raman tag labeling and SERS-based detection within a microfluidic device, which 
takes advantage of the highly sensitive and reliable quantification capability of the SERS-
based aptasensor. For example, bead-based labeling of AVP with a TAMRA tag can be 
performed by incubating a mixture of AVP and NHS ester-TAMRA with aptamer-
functionalized microbeads, resulting in TAMRA-labeled AVP (TVP) captured by 
aptamer on microbead surfaces. After the removal of unreacted molecules, TVP is 
thermally released and transferred to the sensing microchamber in which TVP interacts 
with the aptamer on leaning nanopillars and is analyzed by large area Raman mapping as 
described in Chapter 4. The effects of interference from biological impurities on the 




concentration during or prior to the in-situ labeling step (as described in Chapter 2 and 5), 
or suitable enlargement of a map size in Raman mapping, or combination of both. Such a 
totally integrated system would ultimately enable ultrasensitive detection of AVP at low 
picomolar concentrations from human patient samples in clinical settings, achieved by 
labeling endogenous AVP in a rapid and selective manner followed by SERS-based 
detection of the labeled AVP.  
Graphene-Based Aptasensor. In the complementary approach of using graphene 
nanosensing to SERS, we presented an integrated microfluidic device that combines 
aptamer-based selective preconcentration and conductance-based graphene nanosensing. 
Using the graphene-based aptasensor, we demonstrated label-free detection of AVP in 
buffer at picomolar concentrations (1-500 pM). In the future, our graphene-based 
aptasensor can be further extended to the detection of AVP from human bodily fluids. The 
fundamental concept of the integrated microfluidic device should be readily applicable to 
such complex samples. The likely decrease in detection sensitivity and reproducibility, 
which may arise from low analyte abundance in bodily fluids with high biological 
complexity, could be addressed by optimizing the device design (e.g., shape and 
dimensions) and experimental protocols (e.g., infused sample volume and flow rate) to 
effect sufficient and selective preconcentration of endogenous AVP, thus ultimately 
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